APR‐246 TRIGGERS FERRITINOPHAGY AND FERROPTOSIS OF DIFFUSE LARGE B‐CELL LYMPHOMA CELLS WITH DISTINCT TP53 MUTATIONS (English)
- New search for: Fei, Y.
- New search for: Wang, X.
- New search for: Hong, Y.
- New search for: Li, L.
- New search for: Qiu, L.
- New search for: Qian, Z.
- New search for: Zhou, S.
- New search for: Zhang, H.
- New search for: Fei, Y.
- New search for: Wang, X.
- New search for: Hong, Y.
- New search for: Li, L.
- New search for: Qiu, L.
- New search for: Qian, Z.
- New search for: Zhou, S.
- New search for: Zhang, H.
In:
Hematological Oncology
;
41
;
794-795
;
2023
- Article (Journal) / Electronic Resource
-
Title:APR‐246 TRIGGERS FERRITINOPHAGY AND FERROPTOSIS OF DIFFUSE LARGE B‐CELL LYMPHOMA CELLS WITH DISTINCT TP53 MUTATIONS
-
Contributors:
-
Published in:Hematological Oncology ; 41 ; 794-795
-
Publisher:
-
Publication date:2023-06-01
-
Size:2 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
-
Source:
Table of contents – Volume 41
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
Issue Information| 2023
- 3
-
Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendationsPassamonti, Francesco / Nicastri, Emanuele / Di Rocco, Alice / Guarini, Attilio / Ibatici, Adalberto / Luminari, Stefano / Mikulska, Malgorzata / Visco, Carlo et al. | 2023
- 4
-
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13–17 June, 2023| 2023
- 4
-
ACKNOWLEDGEMENTS| 2023
- 8
-
SCIENTIFIC PROGRAM (as of May 15, 2023) CONFIDENTIAL| 2023
- 11
-
Advances in positron emission tomography and radiomicsBarrington, Sally F. et al. | 2023
- 16
-
Predictors of clinical evolution of SARS‐CoV‐2 infection in hematological patients: A systematic review and meta‐analysisCarrara, Elena / Razzaboni, Elisa / Azzini, Anna Maria / De Rui, Maria Elena / Pinho Guedes, Mariana Nunes / Gorska, Anna / Giannella, Maddalena / Bussini, Linda / Bartoletti, Michele / Arbizzani, Federica et al. | 2023
- 20
-
Cutaneous T‐cell lymphoma—Focus on some problems, and some solutionsBeltraminelli, Helmut et al. | 2023
- 25
-
Management of primary and secondary CNS lymphomaKhwaja, Jahanzaib / Cwynarski, Kate et al. | 2023
- 26
-
DNA damage accumulation and repair defects in FLT3‐ITD acute myeloid leukemia: Implications for clonal evolution and disease progressionLagunas‐Rangel, Francisco Alejandro et al. | 2023
- 30
-
ELUCIDATING THE ENIGMATIC PATHOBIOLOGY OF HODGKIN LYMPHOMAKüppers, R. et al. | 2023
- 30
-
LESSONS LEARNED FROM THE GENETIC HETEROGENEITY OF LYMPHOID MALIGNANCIESShipp, M. A. et al. | 2023
- 30
-
25 YEARS OF ANTIBODY TREATMENTS FOR LYMPHOMAJohnson, P. M. W. et al. | 2023
- 31
-
FRONTLINE INTENSIFIED ABVD DEMONSTRATES SUPERIOR EFFICACY THAN PET‐ADAPTED ABVD IN ADVANCED HODGKIN LYMPHOMA: THE FIL‐ROUGE PHASE 3 TRIAL BY THE FONDAZIONE ITALIANA LINFOMIPinto, A. / Corazzelli, G. / Evangelista, A. / Patti, C. / De Lorenzo, S. / Re, A. / Merli, F. / Botto, B. / Tarantini, G. / Guarini, A. et al. | 2023
- 33
-
NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826Herrera, A. F. / LeBlanc, M. / Castellino, S. M. / Li, H. / Rutherford, S. C. / Evens, A. M. / Davison, K. / Punnett, A. / Hodgson, D. / Parsons, S. K. et al. | 2023
- 35
-
FOURTH GENERATION HUCART19‐IL18 PRODUCES DURABLE RESPONSES IN LYMPHOMA PATIENTS PREVIOUSLY RELAPSED/REFRACTORY TO ANTI‐CD19 CAR T‐CELL THERAPYSvoboda, J. / Landsburg, D. L. / Chong, E. A. / Barta, S. K. / Nasta, S. D. / Ruella, M. / Hexner, E. O. / Marshall, A. / Leskowitz, R. / Four, M. et al. | 2023
- 36
-
Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approachesSilkenstedt, Elisabeth / Dreyling, Martin et al. | 2023
- 37
-
SINGLE CELL OMICS IN THE STUDY OF B CELL LYMPHOMABasso, K. et al. | 2023
- 37
-
CIRCULATING TUMOR DNA (LIQUID BIOPSY)Rossi, D. et al. | 2023
- 37
-
ABSTRACT INCLUDED IN THE LBA SECTION| 2023
- 38
-
SUBCLONAL HETEROGENEITY DRIVING PROGRESSION AND TRANSFORMATION IN CHRONIC LYMPHOCYTIC LEUKEMIACampo, E. et al. | 2023
- 38
-
THE TUMOR MICROENVIRONMENT OF HODGKIN LYMPHOMA AT SINGLE CELL RESOLUTIONSteidl, C. G. et al. | 2023
- 38
-
TRAJECTORIES OF LYMPHOMAGENESISNadel, B. et al. | 2023
- 39
-
DIVERSITY OF INTRATUMORAL REGULATORY T CELLS IN B‐CELL NON‐HODGKIN LYMPHOMASpasevska, I. / Sharma, A. / Steen, C. B. / Josefsson, S. E. / Blaker, Y. N. / Kolstad, A. / Rustad, E. H. / Meyer, S. / Chellappa, S. / Kushekhar, K. et al. | 2023
- 39
-
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphomaDesai, Sanjal H. / Mwangi, Raphael / Smith, Alexandra N. / Maurer, Matthew J. / Farooq, Umar / King, Rebecca L. / Cerhan, James R. / Feldman, Andrew L. / Habermann, Thomas M. / Thompson, Carrie A. et al. | 2023
- 40
-
IDENTIFICATION OF GENOMIC BIOMARKERS OF DISEASE PROGRESSION AND SURVIVAL IN NEWLY‐DIAGNOSED PRIMARY CNS LYMPHOMAMo, S. / Geng, H. / Ballapuram, A. / Chen, L. / Lu, M. / Devine, W. P. / Wen, K. W. / Solomon, D. / Rubenstein, J. et al. | 2023
- 41
-
CONSOLIDATIVE HCT‐ASCT IS SUPERIOR TO NON‐MYELOABLATIVE CHEMO‐IMMUNOTHERAPY IN NEWLY‐DIAGNOSED PCNSL ‐ UPDATED RESULTS OF THE RANDOMIZED PHASE III MATRIX/IELSG43 TRIALIllerhaus, G. / Ferreri, A. / Binder, M. / Borchmann, P. / Hasenkamp, J. / Stilgenbauer, S. / Roeth, A. / Weber, T. / Egerer, G. / Ernst, T. et al. | 2023
- 43
-
CAR‐T CELLS RADICALLY MODIFY THE MANAGEMENT OF RELAPSED/REFRACTORY PRIMARY CEREBRAL LYMPHOMAS. REAL LIFE RESULTS OF THE FRENCH LOC NETWORKChoquet, S. / Soussain, C. / Waultier‐Rascalou, A. / Xuan, K. Hoang / Guffroy, B. / Ahle, G. / Barrie, M. / Galicier, L. / Diblasi, R. / Ursu, R. et al. | 2023
- 43
-
Update on follicular lymphomaFriedberg, Jonathan W. et al. | 2023
- 44
-
PHASE 2 STUDY OF IBRUTINIB WITH TEMOZOLOMIDE, ETOPOSIDE, LIPOSOMAL DOXORUBICIN, DEXAMETHASONE, RITUXIMAB (TEDDI‐R) FOR SECONDARY CNS LYMPHOMARoschewski, M. / Simard, J. / Melani, C. / Lakhotia, R. / Phelan, J. D. / Pittaluga, S. / Muppidi, J. R. / Lionakis, M. S. / Peer, C. / Pradhan, A. et al. | 2023
- 46
-
FIVE‐YEAR RESULTS OF A PHASE 2 STUDY OF CNS‐ORIENTED THERAPY WITH R‐CHOP FOR UNTREATED INTRAVASCULAR LARGE B‐CELL LYMPHOMA: FINAL ANALYSIS OF THE PRIMEUR‐IVL STUDYShimada, K. / Yamaguchi, M. / Kuwatsuka, Y. / Matsue, K. / Sato, K. / Kusumoto, S. / Nagai, H. / Takizawa, J. / Fukuhara, N. / Nagafuji, K. et al. | 2023
- 48
-
Post‐transplant lymphoproliferative disease in children, adolescents, and young adultsGross, Thomas G. / Rubinstein, Jeremy D. et al. | 2023
- 48
-
A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPYDavies, A. J. / Zucca, E. / Ceriani, L. / Kryachok, I. / Ciccone, G. / Botto, B. / Balzarotti, M. / Tucci, A. / Rusconi, C. / Usai, S. V. et al. | 2023
- 50
-
R‐CODOX‐M/R‐IVAC VERSUS DA‐EPOCH‐R IN PATIENTS WITH NEWLY DIAGNOSED HIGH‐RISK BURKITT LYMPHOMA: FINAL RESULTS OF A MULTI‐CENTER RANDOMIZED HOVON/SAKK TRIALChamuleau, M. / Stenner, F. / Chitu, D. / Novak, U. / Minnema, M. / Visser, O. / Stevens, W. / Zenz, T. / van Imhoff, G. / Wu, K. et al. | 2023
- 50
-
Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biasesSoscia, Roberta / Della Starza, Irene / De Novi, Lucia Anna / Ilari, Caterina / Ansuinelli, Michela / Cavalli, Marzia / Bellomarino, Vittorio / Cafforio, Luciana / Di Trani, Mariangela / Cazzaniga, Giovanni et al. | 2023
- 51
-
BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH‐RISK LARGE B‐CELL LYMPHOMA (NLG‐LBC‐06 PHASE II TRIAL): IMPACT OF CTDNA AND TP53 ABERRATIONS ON CLINICAL OUTCOMELeppa, S. / Meriranta, L. / Arffman, M. / Jørgensen, J. / Karjalainen‐Lindsberg, M. / Beiske, K. / Pedersen, M. / Drott, K. / Fluge, Ø. / Jyrkkiö, S. et al. | 2023
- 52
-
PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA‐7 STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAWestin, J. R. / Oluwole, O. O. / Kersten, M. J. / Miklos, D. B. / Perales, M.‐A. / Ghobadi, A. / Rapoport, A. P. / Sureda, A. / Jacobson, C. A. / Farooq, U. et al. | 2023
- 54
-
FOXO1‐RICTOR AXIS INDUCES AKT PHOSPHORYLATION DURING CLL CELL ADAPTATION TO BCR INHIBITORS: IMPLICATIONS FOR COMBINATORIAL THERAPYOndrisova, L. / Seda, V. / Hoferkova, E. / Chiodin, G. / Hlavac, K. / Kostalova, L. / Pavlasova, G. Mladonicka / Filip, D. / Zeni, P. Faria / Oppelt, J. et al. | 2023
- 56
-
IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIALLangerbeins, P. / Robrecht, S. / Nieper, P. / Cramer, P. / Fürstenau, M. / Al‐Sawaf, O. / Fink, A. / Kreuzer, K. / Vehling‐Kaiser, U. / Tausch, E. et al. | 2023
- 57
-
Are we reaching the maximum cure rate for Hodgkin lymphoma?Johnson, Peter W. M. et al. | 2023
- 58
-
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDYAl‐Sawaf, O. / Robrecht, S. / Zhang, C. / Olivieri, S. / Chang, Y. M. / Fink, A. M. / Tausch, E. / Schneider, C. / Ritgen, M. / Kreuzer, K. et al. | 2023
- 60
-
LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): PRIMARY ANALYSIS OF TRANSCEND CLL 004Siddiqi, T. / Maloney, D. G. / Kenderian, S. S. / Brander, D. M. / Dorritie, K. / Soumerai, J. / Riedell, P. A. / Shah, N. N. / Nath, R. / Fakhri, B. et al. | 2023
- 61
-
Exosomal NAMPT from chronic lymphocytic leukemia cells orchestrate monocyte survival and phenotype under endoplasmic reticulum stressNi, Jing / Zhang, Ju / Liu, Jiatao / Fan, Lulu / Lin, Xiao / Yu, Hanqing / Sun, Guoping et al. | 2023
- 62
-
EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROMEFrustaci, A. M. / Montillo, M. / Rossi, D. / Zinzani, P. L. / Motta, M. / Gaidano, G. / Quaresmini, G. / Scarfò, L. / Pietrasanta, D. / Coscia, M. et al. | 2023
- 62
-
The germinal center in the pathogenesis of B cell lymphomasPasqualucci, Laura et al. | 2023
- 63
-
GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS AND HAS A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RICHTER’S TRANSFORMATIONCarlo‐Stella, C. / Hutchings, M. / Offner, F. / Mulvihill, E. / Relf, J. / Byrne, B. / Lundberg, L. / Dickinson, M. et al. | 2023
- 65
-
PRIMARY MEDIASTINAL B‐CELL LYMPHOMA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTSGiulino Roth, L. et al. | 2023
- 65
-
MINIMAL DISSEMINATED AND MINIMAL RESIDUAL DISEASE IN CHILDHOOD AND ADOLESCENT NON‐HODGKIN LYMPHOMAWoessmann, W. et al. | 2023
- 66
-
PHASE 2 KEYNOTE‐667: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE TO FRONT‐LINE CHEMOTHERAPYVinti, L. / Daw, S. / Alvarez, C. Sabado / Fagioli, F. / Beishuizen, A. / Michel, G. / Moleti, M. L. / Cepelova, M. / Thorwarth, A. / Rigaud, C. et al. | 2023
- 67
-
ANALYSIS TREATMENT OUTCOME OF 46 REFRACTORY/RELAPSED PEDIATRIC MATURE B CELL LYMPHOMA PATIENTS‐MULTI‐CENTER EXPERIENCE FROM CHINAZhang, Y. / Huang, S. / Jin, L. / Yang, J. / Hu, B. / Zheng, C. M. / Zhai, W. X. / Wang, S. H. / Li, F. / Yang, X. et al. | 2023
- 68
-
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH REDUCED‐TOXICITY CONDITIONING FOR PEDIATRIC RELAPSED OR REFRACTORY ALK‐POSITIVE ANAPLASTIC LARGE CELL LYMPHOMAKnörr, F. / Zimmermann, M. / Müller, I. / Bader, P. / Lang, P. / Basu, O. / Burkhardt, B. / Beier, R. / Woessmann, W. et al. | 2023
- 69
-
PATTERNS OF PRESENTATION AND OUTCOMES IN STAGE IV HODGKIN LYMPHOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (COG) AHOD1331 TRIALCasey, D. / McCarten, K. / Pei, Q. / Milgrom, S. / Belsky, J. / Cho, S. / Keller, F. / Punnett, A. / Hoppe, B. / Kelly, K. et al. | 2023
- 69
-
LANDSCAPE OF DRIVER MUTATIONS AND THEIR CLINICAL IMPACTS IN CHINESE PEDIATRIC PATIENTS WITH MATURE B‐CELL NON‐HODGKIN'S LYMPHOMA AND T‐CELL LYMPHOBLASTIC LYMPHOMAZheng, Q. / Li, Y. / Liu, Y. / Zhang, Y. / Jin, L. / Yang, J. / Huang, S. / Hu, B. / Liu, R. / Liu, W. et al. | 2023
- 70
-
Lymphomas in pregnancyPirosa, Maria Cristina / Peccatori, Fedro Alessandro et al. | 2023
- 71
-
ALK‐POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WITH VARIANT ALK‐FUSION PARTNER: A POPULATION‐BASED ANALYSES OF THE NHL‐BFM STUDY GROUPDamm‐Welk, C. / Luedersen, J. / Stadt, U. zur / Richter, J. / Oschlies, I. / Klapper, W. / Rosenwald, A. / Kalinova, M. / Simonitsch‐Klupp, I. / Siebert, R. et al. | 2023
- 71
-
LUNG STAGING IN PEDIATRIC HODGKIN LYMPHOMA: STAGING EVALUATION & RESPONSE CRITERIA HARMONIZATION FOR CHILDHOOD, ADOLESCENT & YOUNG ADULT HL (SEARCH FOR CAYAHL) CONSENSUSSeelisch, J. / Alazraki, A. L. / Attarbaschi, A. / Beishuizen, A. / Cho, S. / de Alarcon, P. A. / Dieckmann, K. / Drachtman, R. A. / Ehrhardt, M. J. / Georgi, T. et al. | 2023
- 71
-
Long term outcomes of gastric mucosa‐associated lymphoid tissue lymphoma treated with radiotherapy: A multi‐center retrospective cohort studySmith, Clinton D. / Gupta, Sanjiv / Sinn Chin, Yaw / Thompson, Stephen R. et al. | 2023
- 73
-
QUALITY OF LIFE IN PEDIATRIC HIGH‐RISK HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB‐BASED INTENSIVE CHEMOTHERAPY—COMPARISON TO HISTORICAL TREATMENT COHORT AND HEALTHY PEERSFeraco, A. M. / Mandrell, B. / Friedmann, A. / Marks, L. / Li, Y. / Weinstein, H. J. / Link, M. P. / Flerlage, J. E. et al. | 2023
- 75
-
QUANTITATIVE WHOLE‐BODY MRI FOR PREDICTING TREATMENT OUTCOME IN PEDIATRIC PATIENTS WITH AGGRESSIVE NON‐HODGKIN LYMPHOMA UNDERGOING CHIMERIC ANTIGEN RECEPTOR T CELL THERAPYLi, Y. X. / Zhang, Y. H. / Zheng, B. J. / Liu, Y. / Hu, B. / Zhu, Q. et al. | 2023
- 75
-
Reappraisal of the role of radiation therapy in lymphoma treatmentSpecht, Lena et al. | 2023
- 76
-
THE GENETIC SUBTYPES AND THE TUMOR MICROENVIRONMENT SIGNATURES ARE ASSOCIATED WITH DISTINCT OUTCOMES IN PERIPHERAL T‐CELL LYMPHOMASuehara, Y. / Sakamoto, K. / Fujisawa, M. / Fukumoto, K. / Makishima, K. / Suma, S. / Abe, Y. / Sugio, T. / Narita, K. / Nakamura, N. et al. | 2023
- 77
-
ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA: FINAL ANALYSIS OF THE RO‐CHOP TRIALCamus, V. / Thieblemont, C. / Gaulard, P. / Cheminant, M. / Casasnovas, R. / Ysebaert, L. / Damaj, G. L. / Guidez, S. / Pica, G. M. / Kim, W. S. et al. | 2023
- 78
-
TARGETED AGENTS COMBINED WITH CHOP COMPARED WITH CHOP AS THE FIRST‐LINE THERAPY FOR PERIPHERAL T‐CELL LYMPHOMA: PRELIMINARY RESULTS FROM A PHASE 2 GUIDANCE‐03 TRIALCai, M. / Cheng, S. / Jing, H. / Cui, G. / Niu, T. / Wang, X. / Shen, J. / Huang, L. / Huang, Y. / Wang, L. et al. | 2023
- 78
-
The elderly prognostic index predicts early mortality in older patients with diffuse large B‐cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana LinfomiCencini, Emanuele / Tucci, Alessandra / Puccini, Benedetta / Cavallo, Federica / Luminari, Stefano / Usai, Sara Veronica / Fabbri, Alberto / Pennese, Elsa / Marino, Dario / Zilioli, Vittorio Ruggero et al. | 2023
- 79
-
GOLIDOCITINIB IN TREATING REFRACTORY OR RELAPSED PERIPHERAL T‐CELL LYMPHOMA: PRIMARY ANALYSIS OF THE MULTINATIONAL PIVOTAL STUDY RESULTS (JACKPOT8)Kim, W. / Cai, Q. / Song, Y. / Malpica, L. / Mehta‐Shah, N. / Zhao, W. / Zhou, K. / Wu, J. / Zhang, H. / Ding, K. et al. | 2023
- 80
-
FIRST IN HUMAN STUDY OF AUTO4, A TRBC1‐TRAGETTING CART T CELL THERAPY IN RELAPSED/REFRACTORY TRBC1‐POSITIVE PERIPHERAL T‐CELL LYMPHOMACwynarski, K. / Iacoboni, G. / Tholouili, E. / Menne, T. / Irvine, D. / Balasubramaniam, N. / Wood, L. / Stephens, C. / Shang, J. / Xue, E. et al. | 2023
- 81
-
PHASE 2 STUDY OF ANBAL‐CEL, NOVEL ANTI‐CD19 CAR‐T THERAPY WITH DUAL SILENCING OF PD‐1 AND TIGIT IN RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA ‐ INTERIM ANALYSIS RESULTKim, W. / Kim, S. J. / Yoon, D. H. / Eom, H. / Yang, D. / Yoon, S. E. / Cho, H. / Lee, H. / Jung, J. / Yoon, S. et al. | 2023
- 82
-
POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMAMagen, H. / Fried, S. / Itzhaki, O. / Shem‐Tov, N. / Danylesko, I. / Yerushalmi, R. / Marcus, R. / Shouval, R. / Nevo, L. / Shapira‐Frommer, R. et al. | 2023
- 82
-
Peripheral T‐cell lymphomasBroccoli, Alessandro / Zinzani, Pier Luigi et al. | 2023
- 83
-
OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL)Ramos, C. A. / Quach, D. H. / Lulla, P. D. / Rouce, R. H. / Sharma, S. / Ganesh, H. R. / Nouraee, N. / Briones, Y. D. / Becerra‐Dominguez, L. / Thakkar, S. G. et al. | 2023
- 85
-
DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (R/R LBCL)Locke, F. L. / Lekakis, L. / Eradat, H. / Munoz, J. / Tees, M. / de Vos, S. / Nath, R. / Stevens, D. / Malik, S. / Popplewell, L. et al. | 2023
- 87
-
HIGH EFFICACY AND FAVORABLE SAFETY OF 3RD GENERATION CD20 CAR‐T (MB‐106) FOR OUTPATIENT TREATMENT OF FOLLICULAR LYMPHOMA (FL)—RESULTS OF A SINGLE‐INSTITUTION TRIALShadman, M. / Yeung, C. / Redman, M. / Lee, S. Y. / Lee, D. H. / Qian, D. H. / Ra, S. / Ujjani, C. S. / Dezube, B. J. / Warren, E. H. et al. | 2023
- 88
-
EPIGENETIC BASIS AND THERAPY OF DLBCLMelnick, A. M. et al. | 2023
- 88
-
Autologous hematopoietic cell transplantation versus whole‐brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta‐analysisEpperla, Narendranath / Reljic, Tea / Chowdhury, Sayan Mullick / Ferreri, Andrés J. M. / Kumar, Ambuj / Hamadani, Mehdi et al. | 2023
- 88
-
Marginal zone lymphomasZucca, Emanuele / Rossi, Davide / Bertoni, Francesco et al. | 2023
- 89
-
EPIGENETIC REGULATION OF IMMUNE MICROENVIRONMENT INTERACTIONS IN LYMPHOMAGreen, M. R. et al. | 2023
- 89
-
EPIGENETIC BASIS AND THERAPY OF FOLLICULAR HELPER T‐CELL LYMPHOMASLemonnier, F. et al. | 2023
- 89
-
SUPER‐ENHANCER HYPERMUTATION IN DLBCL: ROLE OF ALTERATIONS IN THE GLUCOCORTICOID RECEPTOR PATHWAYBal, E. / Corinaldesi, C. / Holmes, A. B / Pasqualucci, L. / Basso, K. / Dalla‐Favera, R. et al. | 2023
- 90
-
BASELINE PET RADIOMICS OUTPERFORMS CLINICAL RISK SCORES IN PREDICTING PRIMARY MEDIASTINAL B‐CELL LYMPHOMA OUTCOME: INSIGHTS FROM THE IELSG37 STUDYCeriani, L. / Milan, L. / Cascione, L. / Di Rocco, A. / Kryachok, I. / Davies, A. J. / Stathis, A. / Johnson, P.W.M. / Ciccone, G. / Martelli, M. et al. | 2023
- 91
-
RISK STRATIFICATION OF DLBCL WITH MVED2 SCORE USING INTEGRATIVE HOST ADIPOSE DENSITY AND METABOLIC TUMOR CHARACTERISTICS COMPARED TO OTHER INDEXESThieblemont, C. / Chartier, L. / Vercellino, L. / Deux, J. / Casasnovas, O. / Judet, A. / Baud, V. / Tilly, H. / Cottereau, A. et al. | 2023
- 92
-
Novel agents in relapsed/refractory diffuse large B‐cell lymphomaVarma, Gaurav / Goldstein, Jordan / Advani, Ranjana H. et al. | 2023
- 92
-
BASELINE SUV AND EARLY RESPONSE, BUT NOT MTV, ARE ASSOCIATED WITH OUTCOME IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH NIVOLUMAB IN THE CHECKMATE 205 TRIALBarrington, S. F. / Fischer, B. M. / Kirkwood, A. A. / Grootendorst, D. / Akyol, A. / Ansell, S. M. / Armand, P. / Schwartz, L. H. et al. | 2023
- 93
-
DYNAMICS OF RADIOMIC FEATURES FOLLOWING BRIDGING THERAPY DETERMINE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY OUTCOMEImber, B. S. / Silverman, E. A. / Leithner, D. / Hubbeling, H. / Shah, G. L. / Fregonese, B. / Sanin, B. W. / Tomas, A. A. / Parascondola, A. / Saldia, A. et al. | 2023
- 94
-
RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES OUTCOME PREDICTION IN FOLLICULAR LYMPHOMARebaud, L. / Capobianco, N. / Spottiswoode, B. / Cottereau, A. / Trotman, J. / Feugier, P. / Nastoupil, L. J. / Bachy, E. / Flinn, I. W. / Haioun, C. et al. | 2023
- 95
-
GENETICALLY DISTINCT PATHOGENESIS OF EPSTEIN‐BARR VIRUS (EBV)‐POSITIVE VERSUS EBV‐NEGATIVE CLASSICAL HODGKIN (CHL) LYMPHOMAGomez, K. / Schiavoni, G. / Nam, Y. / Reynier, J. / Khamnei, C. / Aitken, M. / van Noesel, C. / Falini, B. / Pasqualucci, L. / Rabadan, R. et al. | 2023
- 96
-
DISTINCT HODGKIN LYMPHOMA SUBTYPES IDENTIFIED BY NONINVASIVE GENOMIC PROFILINGAlig, S. K. / Esfahani, M. Shahrokh / Garofalo, A. / Li, M. Y. / Rossi, C. / Adams, R. / Binkley, M. S. / Jin, M. C. / Olsen, M. / Telenius, A. et al. | 2023
- 97
-
Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab eraVassilakopoulos, Theodoros P. / Panitsas, Fotios / Mellios, Zois / Apostolidis, John / Michael, Michalis / Gurion, Ronit / Ferhanoglu, Burhan / Hatzimichael, Eleftheria / Karakatsanis, Stamatios / Dimou, Maria et al. | 2023
- 99
-
DUAL TARGETING OF HODGKIN’S LYMPHOMA BY ANTI‐CD30 CAR‐T CELLS CO‐TRANSDUCED WITH AN ANTI‐PDL1 COSTIMULATORY RECEPTOR TO OVERCOME THE IMMUNOSUPPRESSIVE MICROENVIRONMENTPerriello, V. M. / Martarelli, N. / Gentili, M. / Capurro, M. / Marra, A. / Erol, G. / Gobbi, M. / Tiacci, E. / Falini, B. et al. | 2023
- 100
-
THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITECTURAL PATTERNS FOR NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA: AN INTERNATIONAL STUDY BY GLOWBinkley, M. S. / Flerlage, J. E / Borchmann, P. / Fuchs, M. / Hartmann, S. / Eich, H. T. / Savage, K. J. / Lo, A. / Skinnider, B. / Akhtar, S. et al. | 2023
- 102
-
MARGINAL ZONE LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (MZL‐IPI): A PROGNOSTIC SCORE FOR THE ENTIRE SPECTRUM OF MARGINAL ZONE LYMPHOMAS. A FIL AND SPORE‐MER STUDYLuminari, S. / Bommier, C. / Fabbri, N. / Nizzoli, M. E. / Maurer, M. J. / Tarantino, V. / Ferrero, S. / Rattotti, S. / Merli, M. / Ferrari, A. et al. | 2023
- 103
-
STAGING FDG‐AVIDITY IN EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL) BY DISEASE LOCATIONAlderuccio, J. P. / Saul, E. Edelman / Stanchina, M. / Sassi, R. Hennemann / Zhao, W. / Moskowitz, C. / Reis, I. / Kuker, R. / Lossos, I. / Polar, M. et al. | 2023
- 104
-
RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS: PLANNED SUBSET ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDYThieblemont, C. / Lamy, T. / Tani, M. / Krzisch, D. / Reda, G. / Tedeschi, A. / Usai, S. V. / Guarini, A. / Bijou, F. / Stathis, A. et al. | 2023
- 106
-
THE IELSG39 TRIAL: EFFICACY OF FIRST‐LINE CHLAMYDIA PSITTACI ERADICATION WITH A SIX‐MONTH REGIMEN OF DOXYCYCLINE IN PATIENTS WITH STAGE‐I MALT LYMPHOMA OF THE OCULAR ADNEXAEFerreri, A. J. M. / Sassone, M. C. / Cangi, M. G. / Magliacane, G. / Zanussi, S. / Marino, F. / Flospergher, E. / Vicari, N. / Bongiovanni, L. / Cin, E. Dal et al. | 2023
- 107
-
IMMUNOTHERAPY ALONE VERSUS CHEMOIMMUNOTHERAPY AS FIRST‐LINE TREATMENT OF MARGINAL ZONE LYMPHOMA (MZL): A REAL‐WORLD ANALYSISOlszewski, A. J. / Epperla, N. / Chihara, D. / Ollila, T. et al. | 2023
- 107
-
The evolving therapy of DLBCL: Bispecific antibodiesHutchings, Martin et al. | 2023
- 108
-
A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphomaCarlo‐Stella, Carmelo / Zinzani, Pier Luigi / Sureda, Anna / Araújo, Luis / Casasnovas, Olivier / Carpio, Cecilia / Yeh, Su‐Peng / Bouabdallah, Krimo / Cartron, Guillaume / Kim, Won Seog et al. | 2023
- 108
-
BTG2 SUPER‐ENHANCER MUTATIONS DISRUPT TFAP4 BINDING AND DYSREGULATE BTG2 EXPRESSION IN DIFFUSE LARGE B‐CELL LYMPHOMABal, E. / De Simone, P. / Holmes, A. B. / Hilton, L. / Basso, K. / Soni, R. K. / Morin, R. D. / Dalla‐Favera, R. / Pasqualucci, L. et al. | 2023
- 108
-
CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY FOLLICULAR HELPER T‐CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDYLoyaux, R. / Sako, N. / Quang, V. Tran / Bachy, E. / Morschhauser, F. / Cartron, G. / Gressin, R. / Daguindau, N. / Le Gouill, S. / Wolfromm, A. et al. | 2023
- 110
-
MOLECULAR CHARACTERIZATION CONTRIBUTES TO DIAGNOSIS AND PREDICTS OUTCOME IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMAS: A LYSA STUDYCamus, V. / Viailly, P. / Sesques, P. / Drieux, F. / Veresezan, E. / Haioun, C. / Durot, E. / Patey, M. / Rossi, C. / Martin, L. et al. | 2023
- 111
-
GENE EXPRESSION PROFILING OF T(14;18)‐NEGATIVE CD23+ FOLLICLE CENTER LYMPHOMA DEMONSTRATES ACTIVATION OF THE IL4/JAK/STAT6 PATHWAY AND A ROLE IN ITS PATHOGENESISSchade, T. / Nann, D. / Rau, A. / Chott, A. / Leoncini, L. / Fend, F. / Salaverria, I. / Campo, E. / Jaffe, E. / Bonzheim, I. et al. | 2023
- 112
-
CAR T‐cell therapy in large B cell lymphomaBoardman, Alexander P. / Salles, Gilles et al. | 2023
- 112
-
IMMUNOGLOBULIN CLASS DICTATES TRANSFORMATION TRAJECTORY AND BCR STATUS OF MYC/BCL2 DOUBLE‐HIT LYMPHOMA: BIOLOGY AND CLINICAL IMPLICATIONSCasola, S. / Sindaco, P. / Lonardi, S. / Zanardi, F. / Neuman, H. / Lorenzi, L. / Balzarini, P. / Morello, G. / Varano, G. / Bugatti, M. et al. | 2023
- 113
-
1998–2023 TWENTY‐FIVE YEARS OF COMMITMENT TO IMPROVING OUR UNDERSTANDING OF LYMPHOMAZucca, E. et al. | 2023
- 113
-
INTRODUCTION OF LYMPHOMA DATABASE OF NATIONAL HEALTH COMMISSION OF THE PEOPLE'S REPUBLIC OF CHINALiu, W. / Song, Y. / Zhu, J. / Ma, J. / Ma, Z. / Yang, A. et al. | 2023
- 114
-
SMART START WITH TISLELIZUMAB AS THE FRONT‐LINE TREATMENT IN PATIENTS WITH HIGH‐RISK STAGE IIB AND ADVANCED‐STAGE CLASSICAL HODGKIN LYMPHOMAWang, Y. / Yang, H. / Sun, P. / Nie, M. / Li, J. / Cao, J. / Huang, Y. / Li, Z. et al. | 2023
- 115
-
ROLE OF CHECKPOINT INHIBITION IN GERMANYBorchmann, P. et al. | 2023
- 115
-
NEW DRUG DEVELOPMENT IN LYMPHOMA OF CHINA IS GOING GLOBALZhou, K. et al. | 2023
- 116
-
NEW TRENDS IN LYMPHOMA TREATMENT IN WESTERN COUNTRIESZinzani, P. L. et al. | 2023
- 116
-
A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016Shadman, M. / Li, H. / Rimsza, L. / Leonard, J. P. / Kaminski, M. S / Spier, C. M / Gopal, A. K / Dakhil, S. / LeBlanc, M. / Smith, S. M. et al. | 2023
- 117
-
SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPYØstenstad, B. / Pirosa, M. C. / Schär, S. / Brodtkorb, M. / Wahlin, B. E. / Hernberg, M. / Pedersen, M. / Stathis, A. / Zander, T. / Novak, U. et al. | 2023
- 119
-
Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemiaChen, Shih‐Shih / Chiorazzi, Nicholas et al. | 2023
- 119
-
ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDYZinzani, P. L. / Mayer, J. / Trotman, J. / Bijou, F. / de Oliveira, A. C. / Song, Y. / Zhang, Q. / Merli, M. / Bouabdallah, K. / Ganly, P. S. et al. | 2023
- 120
-
Effects of the BTN162b2 mRNA COVID‐19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemiaFiorcari, Stefania / Atene, Claudio Giacinto / Maffei, Rossana / Mesini, Nicolò / Debbia, Giulia / Colasante, Corrado / Pozzi, Stefano / Barbieri, Emiliano / Maccaferri, Monica / Leonardi, Giovanna et al. | 2023
- 121
-
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2Novelli, S. / Luminari, S. / Taszner, M. / Cho, S. / Le Gouill, S. / Poon, M. / Villasboas, J. C. / Champion, R. / Bachy, E. / Guidez, S. et al. | 2023
- 122
-
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDYSehn, L. H. / Bartlett, N. L. / Matasar, M. / Schuster, S. J. / Assouline, S. / Giri, P. / Kuruvilla, J. / Shadman, M. / Cheah, C. Y. / Fay, K. et al. | 2023
- 125
-
EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUSBelada, D. / Falchi, L. / Leppä, S. / Vermaat, J. S. / Holte, H. / Hutchings, M. / Lugtenburg, P. / de Vos, S. / Abrisqueta, P. / Nijland, M. et al. | 2023
- 127
-
DOES IT MATTER HOW WE NAME LYMPHOMAS?Armitage, J. O. et al. | 2023
- 127
-
HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 T‐CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDYCho, S. / Nair, R. / Jacobs, R. / Devata, S. / Gaballa, S. / Yoon, D. H. / Stevens, D. A. / Kim, J. S. / Shah, N. N. / Brennan, D. M. et al. | 2023
- 128
-
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohortMerli, Michele / Ferrarini, Isacco / Merli, Francesco / Busca, Alessandro / Mina, Roberto / Falini, Brunangelo / Bruna, Riccardo / Cairoli, Roberto / Marchetti, Monia / Romano, Alessandra et al. | 2023
- 129
-
PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)Danilov, A. / Gregory, G. P. / Morschhauser, F. / Cheah, C. Y. / Shah, H. / Jurczak, W. / Olabode, D. / Meyer, S. / Yoon, J. L. / Arduini, S. et al. | 2023
- 129
-
First line therapy of CLLHallek, Michael et al. | 2023
- 131
-
PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)Hertzberg, M. / Kalac, M. / Cheah, C. Y. / Ribrag, V. / Abrisqueta, P. / Opat, S. / Bachy, E. / Ysebaert, L. / Qiu, L. / Yi, S. et al. | 2023
- 132
-
ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITOR SHR2554 IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL): UPDATED OUTCOMES FROM THE FIRST‐IN‐HUMAN PHASE 1 STUDYSong, Y. / Zhu, J. / Jin, Z. / Li, Z. / Liu, Y. / Li, L. / He, C. / Su, H. / Zhou, H. / Li, K. et al. | 2023
- 134
-
OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)Michot, J. M. / Chavez, J. / Carpio, C. / Bachy, E. / Ferrari, S. / Morschhauser, F. / Jørgensen, J. M. / Cordoba, R. / Bories, P. / Patah, P. et al. | 2023
- 136
-
Approach to relapsed CLL including Richter TransformationSeymour, John F. et al. | 2023
- 136
-
COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAHutchings, M. / Dickinson, M. / Carlo‐Stella, C. / Morschhauser, F. / Bosch, F. / Gritti, G. / Townsend, W. / Bartlett, N. L. / Cartron, G. / Ghesquieres, H. et al. | 2023
- 138
-
GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMAHutchings, M. / Avigdor, A. / Sureda, A. / Terol, M. J. / Bosch, F. / Corradini, P. / Larsen, T. Stauffer / Domínguez, A. Rueda / Skarbnik, A. / Jørgensen, J. et al. | 2023
- 139
-
The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor‐based regimens as induction treatment: A real‐world analysisChen, Haimin / Zhou, Nian / Hu, Xiaohua / Wang, Dongjiao / Wei, Wei / Peng, Rong / Chen, Xiaoling / Shi, Haotian / Wu, Lixia / Yu, Wenjun et al. | 2023
- 141
-
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2Poon, M. / Walewski, J. / Kim, T. M. / Cho, S. / Jarque, I. / Iskierka‐Jażdżewska, E. / Prince, H. M. / Oh, S. Y. / Lim, F. / Carpio, C. et al. | 2023
- 142
-
SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: LONGER FOLLOW‐UP FROM THE PIVOTAL EPCORE NHL‐1 TRIALThieblemont, C. / Karimi, Y. / Jurczak, W. / Cheah, C. Y. / Clausen, M. R. / Cunningham, D. / Do, Y. R. / Lewis, D. J. / Gasiorowski, R. / Kim, T. M. et al. | 2023
- 144
-
GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDYDickinson, M. / Carlo‐Stella, C. / Morschhauser, F. / Falchi, L. / Bachy, E. / Cartron, G. / Khan, C. / Tani, M. / Martinez‐Lopez, J. / Bartlett, N. et al. | 2023
- 147
-
BISPECIFIC ANTI‐CD20/19 CAR‐T—ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL—INTERIM ANALYSIS RESULTS OF DALY‐II‐USA STUDYUlrickson, M. / Miklos, D. B. / Maziarz, R. T / Jacobson, C. / Isufi, I. / Ghosh, M. / Perales, M. / Lunning, M. / Hardy, N. M. / Wijatyk, A. et al. | 2023
- 147
-
Intensified conditioning regimens improved disease‐free survival and engraftment after unrelated single‐unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantationKonuma, Takaaki / Kanda, Junya / Uchida, Naoyuki / Nishijima, Akihiko / Tanaka, Masatsugu / Ozawa, Yukiyasu / Sawa, Masashi / Onizuka, Makoto / Ota, Shuichi / Maruyama, Yumiko et al. | 2023
- 147
-
AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDYHouot, R. / Bachy, E. / Cartron, G. / Gros, F. / Morschhauser, F. / Oberic, L. / Gastinne, T. / Feugier, P. / Dulery, R. / Thieblemont, C. et al. | 2023
- 148
-
FIVE‐YEAR UPDATE OF THE FIRST‐LINE IMCL‐2015 GELTAMO STUDY. PROLONGED MOLECULAR AND CLINICAL RESPONSES WERE OBSERVED AFTER MRD‐DRIVEN IBRUTINIB DISCONTINUATIONGiné, E. / Medina‐Herrera, A. / Cruz, F. de la / Ubieto, A. Jiménez / Jiménez, J. López / García‐ Sancho, A. Martín / Terol, M J. / Barca, E. González / Casanova, M. / Fuente, A. de la et al. | 2023
- 150
-
ACALABRUTINIB WITH RITUXIMAB AS FIRST‐LINE THERAPY FOR OLDER PATIENTS WITH MANTLE CELL LYMPHOMA—A PHASE II CLINICAL TRIALJain, P. / Ok, C. y. / Fetooh, A. / Nastoupil, L. / Westin, J. / Hill, H. A. / Nair, R. / Iyer, S. P. / Steiner, R. E. / Lee, H. J. et al. | 2023
- 151
-
VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.Sarkozy, C. / Thieblemont, C. / Oberic, L. / Moreau, A. / Bouabdallah, K. / Damaj, G. / Gastine, T. / Ribrag, V. / Casasnovas, O. / Haioun, C. et al. | 2023
- 152
-
IBRUTINIB‐RITUXIMAB AND VENETOCLAX (IRV) FOLLOWED BY RISK‐STRATIFIED R‐HYPERCVAD/MTX IN YOUNG PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA—PHASE‐II WINDOW‐2 TRIALWang, M. L. / Lee, H. J. / Fetooh, A. / Nair, R. / Ok, C. Y. / Hill, H. A. / Iyer, S. P / Steiner, R. E. / Westin, J. / Nastoupil, L. et al. | 2023
- 153
-
PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENTCheah, C. Y. / Shah, N. N. / Jurczak, W. / Zinzani, P. Luigi / Eyre, T. A. / Ujjani, C. S. / Izutsu, K. / Ma, S. / Flinn, I. / Alencar, A. J. et al. | 2023
- 156
-
OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI‐INSTITUTION RETROSPECTIVE ANALYSISMessmer, M. / Stack, A. / Deng, M. / Handorf, E. / Kapoor, N. / Sawalha, Y. / Bock, A. M. / Wang, Y. / Graf, K. / Greenwell, B. et al. | 2023
- 158
-
CORRELATION BETWEEN PROGRESSION‐FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM GHSG TRIALSBröckelmann, P. J. / Müller, H. / Gillessen, S. / Jacob, A. / Momotow, J. / Damaschin, C. / Ferdinandus, J. / Yang, X. / Fuchs, M. / Kobe, C. et al. | 2023
- 159
-
EARLY FDG‐PET ADAPTED TREATMENT OF LIMITED STAGE HODGKIN LYMPHOMA (HL): 10Y LONG TERM FOLLOW‐UP ANALYSIS OF THE RANDOMIZED INTERGROUP EORTC/LYSA/FIL H10 TRIALFederico, M. / Fortpied, C. / Stepanishyna, Y. / Gotti, M. / van der Maazen, R. / Amorin, S. / Re, A. / Plattel, W. / Lazarovici, J. / Merli, F. et al. | 2023
- 159
-
Co‐mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndromeRen, Yanling / Lang, Wei / Mei, Chen / Luo, Yingwan / Ye, Li / Wang, Lu / Zhou, Xinping / Xu, Gaixiang / Ma, Liya / Jin, Jie et al. | 2023
- 160
-
PEMBROLIZUMAB AS FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD‐INELIGIBLE PATIENTS, ALLOWS SUBSEQUENT THERAPY, AND GIVES ADEQUATE SURVIVAL.Dickinson, M. J. / Trotman, J. / Berkahn, L. / Butler, J. / Bressel, M. / Neeson, P. / Minson, A. et al. | 2023
- 161
-
PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N‐AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMATorka, P. / Feldman, T. / Savage, K. / Ganesan, N. / Hancock, H. / Davey, T. / Perez, L. / Santarosa, A. / Subzwari, S. / Capadona, C. et al. | 2023
- 162
-
AVELUMAB MONOTHERAPY FOLLOWED BY A PET ADAPTED CHEMOTHERAPY APPROACH IN THE FIRST LINE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA: INITIAL RESULTS FROM THE AVENUE WINDOW STUDYCollins, G. P. / Hawkes, E. A. / Kirkwood, A. A. / Clifton‐Hadley, L. / Tyson, C. / Barsoum, E. / Pettengell, R. / Medd, P. G. / McKay, P. / Miall, F. et al. | 2023
- 163
-
FAVEZELIMAB PLUS PEMBROLIZUMAB IN ANTI–PD‐1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMABArmand, P. / Zinzani, P. L. / Timmerman, J. / Johnson, N. / Lavie, D. / Thiagarajan, K. / Topp, B. / Pillai, P. / Herrera, A. F. et al. | 2023
- 165
-
SAKK 38/19: ASSESSING A CTDNA AND PET‐ORIENTED THERAPY IN PATIENTS WITH DLBCL. A MULTICENTER, OPEN‐LABEL, PHASE II TRIALStathis, A. / Hitz, F. / Schär, S. / Novak, U. / Fischer, N. / Mey, U. / Gritti, G. / Zander, T. / Lang, N. / Cairoli, A. et al. | 2023
- 166
-
REMODL‐A: A RANDOMISED PHASE II EVALUATION OF MOLECULAR GUIDED THERAPY FOR DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) WITH ACALABRUTINIB — ONGOING TRIALRadhakrishnan, V. S. / Stanton, L. / Caddy, J. / Keyworth, N. / Saunders, G. / Barrans, S. / Rafferty, J. / Joyce, T. / Collins, G. P. / Barrington, S. et al. | 2023
- 167
-
Brentuximab Vedotin‐Nivolumab alone and then with Rituximab‐Cyclophosphamide‐Doxorubicin‐Prednisone as Frontline Therapy of Primary Mediastinal Large B‐cell LymphomaSteiner, R. E. / Strati, P. / Flowers, C. R. / Neelapu, S. S. / Green, M. / Nastoupil, L. J. / Hagemeister, F. B. / Feng, L. / Ahmed, S. / Nair, R. et al. | 2023
- 167
-
Prognostic factors in patients with bone marrow hemophagocytosis and its association with hematologic malignanciesJiang, Jing‐Gu / Liu, Chia‐Jen / Yeh, Chiu‐Mei / Yang, Ching‐Fen / Liu, Yao‐Chung / Wang, Hao‐Yuan / Ko, Po‐Shen / Chen, Po‐Min / Yu, Yuan‐Bin / Gau, Jyh‐Pyng et al. | 2023
- 168
-
MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMASehn, L. / Sarkozy, C. / Song, Y. / Salar, A. / Trotman, J. / Zinzani, P. L. / Zhang, J. / Zhang, W. / Fustier, P. / Delarue, R. et al. | 2023
- 170
-
SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAPavlovsky, A. / Westin, J. / Olszewski, A. J / Fogliatto, L. / Kim, W. S. / Shin, H. / Leão, D. / Jeon, Y. / Norasetthada, L. / Rego, E. et al. | 2023
- 171
-
ZUMA‐23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST‐LINE THERAPY IN PATIENTS WITH HIGH‐RISK LARGE B‐CELL LYMPHOMAWestin, J. / Jacobson, C. A. / Chavez, J. C. / Sureda, A. / Morschhauser, F. / Glaß, B. / Dickinson, M. / Davies, A. / Flinn, I. W. / Maloney, D. G. et al. | 2023
- 174
-
MOLECULAR CLUSTERING ON CTDNA IMPROVES THE PROGNOSTIC STRATIFICATION OF DLBCL PATIENTS COMPARED TO CTDNA LEVELSMoia, R. / Talotta, D. / Dondolin, R. / Almasri, M. / Cosentino, C. / Bruna, R. / Della Starza, I. / Soscia, R. / Bruscaggin, A. / Di Bergamo, L. Terzi et al. | 2023
- 175
-
CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDYHerrera, A. F. / Tracy, S. / Sehn, L. H. / Jardin, F. / Lenz, G. / Trněný, M. / Salles, G. / Flowers, C. R. / Tilly, H. / Sharman, J. P. et al. | 2023
- 177
-
MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALSRoschewski, M. / Kurtz, D. M. / Westin, J. / Lynch, R. C. / Alig, S. K. / Macaulay, C. / Kuffer, C. / Hogan, G. J. / Schultz, A. / Close, S. et al. | 2023
- 178
-
Competitive evolved sub‐clonal BCR::ABL1 and novel MSI2::PC fusion genes in myelodysplastic syndrome with isolated del(5q)Zhang, Yanqing / Liu, Yang / Wang, Tong / Wang, Hui / Chen, Xue / Cao, Panxiang / Ma, Xiaoli / Liu, Mingyue / Xu, Ping / Bi, Hailiang et al. | 2023
- 179
-
EARLY CTDNA CLEARANCE AFTER CAR T‐CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B‐CELL LYMPHOMA : RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDYDelfau‐Larue, M. / Viailly, P. / Cartron, G. / Morschhauser, F. / Gros, F. / Gastinne, T. / Oberic, L. / Bachy, E. / Dulery, R. / Feugier, P. et al. | 2023
- 181
-
CELL‐FREE DNA KINETICS DECIPHER POTENTIAL MECHANISMS OF ACTION OF IBRUTINIB COMBINATION THERAPY IN MANTLE CELL LYMPHOMA (MCL)Khouja, M. / Genuardi, E. / Ferrero, S. / Alessandria, B. / Verhagen, O. J. / Homburg, C. / van der Velden, V. H. / Gameiro, P. / Sanz, R. García / Herrera, A. Medina et al. | 2023
- 182
-
Association of cesarean section with risk of childhood leukemia: A meta‐analysis from an observational studyYang, Yingzhu / Yu, Chiyuan / Fu, Rongrong / Xia, Shishan / Ni, Haixiang / He, Yujing / Zhu, Keying / Sun, Qian et al. | 2023
- 183
-
COMBINED USE OF MINIMAL RESIDUAL DISEASE MONITORING AND FDG‐PET FOR OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIALFerrero, S. / Assanto, G. M. / Durmo, R. / Marcheselli, L. / Mantoan, B. / Pironti, M. / Guerra, L. / Boccomini, C. / Puccini, B. / Pulsoni, A. et al. | 2023
- 185
-
GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDYPatel, K. / Brown, J. R. / Desikan, S. P. / Nguyen, B. / Won, H. / Tantawy, S. I. / McNeely, S. C. / Marella, N. / Ebata, K. / Woyach, J. A. et al. | 2023
- 187
-
SINGLE‐CELL RNA‐SEQ OF CLASSIC HAIRY CELL LEUKEMIA REVEALS DISEASE DRIVERS LINKED TO INTRINSIC TREATMENT RESISTANCE AND IDENTIFIES DUSP1 AS POTENTIAL NEW THERAPEUTIC TARGETBohn, J. / Salcher, S. / Sturm, G. / Kugler, V. / Feichtner, A. / Fritz, A. / Torres‐Quesada, O. / Mair, A. / Scheiber, A. / Jäger, U. et al. | 2023
- 188
-
IL16 PRODUCTION IS A MECHANISM OF RESISTANCE TO BTK INHIBITORS AND TO R‐CHOPArribas, A. / Napoli, S. / Cascione, L. / Sartori, G. / Cannas, E. / Tarantelli, C. / Spriano, F. / Gaudio, E. / Zucchetto, A. / Rossi, F. M. et al. | 2023
- 189
-
HARNESSING BTKI THERAPY BY CDK4/6I CONTROL OF T CELL SURVEILLANCEChen‐Kiang, S. / Di Liberto, M. / Huang, X. / Inghirami, G. / Martin, P. / Elemento, O. et al. | 2023
- 189
-
ENHANCER RNAS (ERNAS) PLAY A ROLE IN THE RESPONSE TO SMALL MOLECULES AND IN THE DEVELOPMENT OF ACQUIRED RESISTANCE IN MARGINAL ZONE LYMPHOMA (MZL)Napoli, S. / Cascione, L. / Ramnarayanan, S. / Guidetti, F. / Arribas, A. / Rinaldi, A. / Johnson, R. / Bertoni, F. et al. | 2023
- 190
-
IMMUNE‐DEPLETED TUMOR MICROENVIRONMENT IS ASSOCIATED WITH POOR OUTCOMES AND BTK INHIBITOR RESISTANCE IN MANTLE CELL LYMPHOMAJain, P. / Nomie, K. / Kotlov, N. / Hill, H. / Ok, C. Y. / Fetooh, A. / Kanagal‐Shamanna, R. / Vega, F. / Fowler, N. / Wang, M. et al. | 2023
- 192
-
CHROMATIN ACCESSIBILITY PROFILING TO INCREASE DIAGNOSTIC ACCURACY AND REFINE CELL‐OF‐ORIGIN CLASSIFICATION OF MATURE T‐CELL LYMPHOMASJulia, E. / Mareschal, S. / Chebel, A. / Camille, G. / Missaglia, E. / Rattina, V. / Lours, C. / Testard, Q. / Tschantz, M. / Sebai, S. et al. | 2023
- 192
-
Diffuse large B‐cell lymphoma of the Waldeyer's ring: A U.S. population‐based survival analysisFlorindez, Jorge A. / Lossos, Izidore S. / Alderuccio, Juan Pablo et al. | 2023
- 192
-
LACK OF SMARCB1 EXPRESSION CHARACTERIZES A SUBSET OF PERIPHERAL T‐CELL LYMPHOMAS ENRICHED IN CHILDREN AND YOUNG ADULTSFischer, A. / Moreno, N. / Interlandi, M. / Albert, T. K. / Mormann, J. / Glaser, S. / Patil, P. / Balbach, S. / Wagener, R. / Bens, S. et al. | 2023
- 193
-
BRCA1/2 MUTATIONS IMPACT ON THE DEVELOPMENT OF BREAST IMPLANT‐ASSOCIATED LYMPHOMA (BIA‐ALCL) IN WOMEN WITH BREAST CANCER RECONSTRUCTED WITH TEXTURED BREAST IMPLANTSGhione, P. / Arcila, M. / Joseph, V. / Dogan, A. / Cordeiro, P. / Salles, G. / de Jong, D. / Horwitz, S. / Mandelker, D. / van Leeuwen, F. et al. | 2023
- 194
-
A PHASE 2 TRIAL OF CHOP WITH ANTI‐CCR4 ANTIBODY MOGAMULIZUMAB FOR ELDERLY PATIENTS WITH CCR4‐POSITIVE ADULT T‐CELL LEUKEMIA/LYMPHOMAUtsunomiya, A. / Kusumoto, S. / Choi, I. / Yoshimitsu, M. / Shimokawa, M. / Suehiro, Y. / Hidaka, T. / Nosaka, K. / Sasaki, H. / Rai, S. et al. | 2023
- 195
-
AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDYKim, W. S. / Shortt, J. / Zinzani, P. L. / Mikhaylova, N. / Marin‐Niebla, A. / Radeski, D. / Ribrag, V. / Domenech, E. Domingo / Sawas, A. / Alexis, K. et al. | 2023
- 196
-
Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classificationKriachok, Iryna / Stepanishyna, Yana / Skrypets, Tetiana / Shokun, Nazar / Martynchyk, Arina / Tytorenko, Iryna / Aleksik, Olena / Krotevych, Mykhailo / Manni, Martina / Federico, Massimo et al. | 2023
- 196
-
LACUTAMAB IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES (MF): EFFICACY RESULTS ACCORDING TO UPDATED LYMPH NODE (LN) CLASSIFICATION IN THE TELLOMAK STUDYKim, Y. H. / Bagot, M. / Ortiz‐Romero, P. L. / Zinzani, P. L. / Beylot‐Barry, M. / Dalle, S. / Jacobsen, E. / Combalia, A. / Huen, A. / Mehta‐Shah, N. et al. | 2023
- 197
-
PROTEOMIC PROFILING IDENTIFIES GRANZYME B INHIBITOR SERPIN B9 AS MEDIATOR OF RESISTANCE TO CAR T‐CELL AND BISPECIFIC ANTIBODY TREATMENT IN NODAL B‐CELL LYMPHOMABrinkmann, B. J. / Roider, T. / Capraz, T. / Knoll, M. / Kolb, C. / Liu, Y. / Müller‐Tidow, C. / Chapuy, B. / Sauer, T. / Schmitt, M. et al. | 2023
- 198
-
CART‐SIE REAL LIFE STUDY: PRIMARY MEDIASTINAL B‐CELL LYMPHOMA (PMBCL) HAVE A SUPERIOR OUTCOME COMPARED TO LARGE B‐CELL LYMPHOMA (LBCL) TREATED WITH AXICABTAGENE CILOLEUCELChiappella, A. / Dodero, A. / Guidetti, A. / Ljevar, S. / Pennisi, M. / Casadei, B. / Galli, E. / Di Rocco, A. / Cutini, I. / Barbui, A. M. et al. | 2023
- 199
-
IMPACT OF RESPONSE TO SYSTEMIC BRIDGING THERAPY ON CLINICAL OUTCOMES AND CYTOKINE PROFILE IN PATIENTS RECEIVING CAR T‐CELL THERAPY FOR AGGRESSIVE B‐CELL LYMPHOMAWills, B. / Shouval, R. / Flynn, J. / Devlin, S. M. / Shah, G. L. / Scordo, M. / P. B. Dahi / Lin, R. J. / Imber, B. / Parascondola, A. et al. | 2023
- 201
-
Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network reportBallotta, Laura / Maccaferri, Monica / De Paoli, Lorenzo / Orsucci, Lorella / Gottardi, Daniela / Chiurazzi, Federico / Reda, Gianluigi / Moia, Riccardo / Cuneo, Antonio / Foà, Robin et al. | 2023
- 201
-
BENDAMUSTINE LYMPHODEPLETION TRIGGERS REDUCED INFLAMMATORY CYTOKINES AND DECREASED TOXICITIES AFTER BOTH 4‐1BB‐ AND CD28‐COSTIMULATED CART19 FOR NON‐HODGKIN LYMPHOMAGhilardi, G. / Paruzzo, L. / Svoboda, J. / Chong, E. A. / Cohen, I. J. / Nasta, S. D. / Landsburg, D. J. / Gerson, J. N. / Carter, J. S. / Barta, S. K. et al. | 2023
- 202
-
PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER AUTOLOGOUS ANTI‐CD19 CAR T CELLS IN LARGE B‐CELL LYMPHOMA: A DESCAR‐T REGISTRY STUDY FORM THE LYSASesques, P. / Di blasi, R. / Legouill, S. / Cartron, G. / Beauvais, D. / Le Bras, F. / Gros, F. / Choquet, S. / Bories, P. / Rubio, M. et al. | 2023
- 204
-
SEVERE HEMATOLOGICAL TOXICITY FOLLOWING CD19 CAR‐T FOR RELAPSED/REFRACTORY LBCL IS ASSOCIATED WITH SUPPRESSIVE IMMUNE DYSREGULATION AND LIMITED CAR‐T EXPANSIONRejeski, K. / Perez, A. / Iacoboni, G. / Blumenberg, V. / Bücklein, V. L. / Völkl, S. / Penack, O. / Albanyan, O. / Petrera, A. / Reid, K. et al. | 2023
- 205
-
High mortality in fully vaccinated hematologic patients treated with anti‐CD20 antibodies during the “Omicron wave” of COVID‐19 pandemicCattaneo, Chiara / Masina, Lorenzo / Pagani, Chiara / Cancelli, Valeria / Daffini, Rosa / Tucci, Alessandra / Rossi, Giuseppe et al. | 2023
- 205
-
MYC/BCL6 DOUBLE HIT LYMPHOMA NEGATIVE FOR T(3;8) BCL6::MYC FUSION IS ASSOCIATED WITH INFERIOR SURVIVAL, IN CONTRAST WITH T(3;8) POSITIVE PSEUDO‐DOUBLE HIT LYMPHOMAMaybury, B. D. / James, L. / Chadderton, N. / Dowds, J. / Venkatadasari, I. / Riley, J. / Qureshi, I. / Talbot, G. / Giles, H. V. / Phillips, N. J. et al. | 2023
- 207
-
HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATEFalchi, L. / Clausen, M. R. / Offner, F. / de Vos, S. / Brody, J. / Linton, K. M. / Snauwaert, S. / Cordoba, R. / Wu, J. / Bykhovski, I. et al. | 2023
- 208
-
WAVELINE‐004: OPEN‐LABEL, PHASE 2 STUDY OF ZILOVERTAMAB VEDOTIN (MK‐2140) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)Fosså, A. / Ozcan, M. / Song, Y. / Lee, S. T. / Mensah, F. / Modi, D. / Kim, W. S. / Paszkiewicz‐Kozik, E. / Sawalha, Y. / Sevindik, O. G. et al. | 2023
- 208
-
Convalescent plasma in oncohematological patientsFocosi, Daniele / Franchini, Massimo / Joyner, Michael J. / Henderson, Jeffrey P. / Casadevall, Arturo et al. | 2023
- 209
-
LONG‐TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS‐2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMACaimi, P. F / Ai, W. Z / Alderuccio, J. P. / Ardeshna, K. M / Hamadani, M. / Hess, B. / Kahl, B. S / Radford, J. / Solh, M. / Stathis, A. et al. | 2023
- 210
-
Response to SARS‐CoV‐2 vaccination and antibodies persistence in multiple myeloma patientsPettine, Loredana / Bortolotti, Marta / Fattizzo, Bruno / Da Vià, Matteo C. / Consonni, Dario / Pompa, Alessandra / Bolli, Niccolò / Baldini, Luca et al. | 2023
- 212
-
LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSENastoupil, L. J. / Kamdar, M. / Chavez, J. C. / Ghesquieres, H. / Ghosh, M. / Holmes, H. / López‐Guillermo, A. / Martínez‐López, J. / Novak, U. / Ribrag, V. et al. | 2023
- 213
-
Reply to “successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients—A Czech multicenter experience”: A case series of SARS‐CoV‐2 Omicron infection and aggressive lymphoma in the Sotrovimab eraCassin, Ramona / Rampi, Nicolo / C, Fidanza / Muscatello, Antonio / Mariani, Bianca / Noto, Alessandro / Rossi, Francesca Gaia / Baldini, Luca et al. | 2023
- 214
-
COMPARATIVE ACCURACY OF ALTERNATIVE EARLY MEASURES OF RESIDUAL DISEASE AFTER CAR19 THERAPY OF RELAPSED/REFRACTORY LBCLSworder, B. J. / Alig, S. K. / Shukla, N. / Garofalo, A. / Macaulay, C. W. / Esfahani, M. Shahrokh / Olsen, M. N. / Hamilton, J. / Hosoya, H. / Hamilton, M. P. et al. | 2023
- 216
-
RITUXIMAB‐CONTAINING COMBINED MODALITY THERAPY IN LIMITED STAGE FOLLICULAR LYMPHOMA: MATURE FOLLOW UP AND DERIVATION OF A NOVEL PROGNOSTIC SCORE FROM THE TROG99.03 TRIALTobin, J. W. / Jurinovic, V. / Tsang, H. / Roos, D. / Tsang, R. / Macann, A. / Davis, S. / Christie, D. / Law, S. / Nath, K. et al. | 2023
- 217
-
RADIOTHERAPY BRIDGING IN LARGE B‐CELL LYMPHOMA PATIENTS RECEIVING CD19 CAR‐T – THE UK EXPERIENCEKuhnl, A. / Roddie, C. / Kirkwood, A. / Chaganti, S. / Norman, J. / Lugthart, S. / Osborne, W. / Gibb, A. / Arias, C. Gonzalez / Latif, A. et al. | 2023
- 218
-
HIGH RATE OF METABOLIC COMPLETE RESPONSE AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE FOLLICULAR LYMPHOMA: INITIAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3)Herfarth, K. / Scholz, C. W. / Hübel, K. / Wirths, S. / Buske, C. / Dürig, J. / Forstpointner, R. / Heidegger, S. / Lenz, G. / König, L. et al. | 2023
- 220
-
VERY LOW DOSE RADIATION THERAPY FOR INDOLENT LYMPHOMA: COMPARING “BIG BOOM” (4GY × 1) VERSUS “BOOM BOOM” (2GY × 2)Hajj, C. / Lee, J. / Boe, L. / Fregonese, B. / Lebow, E. / Wijetunga, N. A. / Hubbeling, H. / Tringale, K. / Freret, M. / Imber, B. et al. | 2023
- 221
-
SALVAGE RADIOTHERAPY IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA AFTER CAR T‐CELL THERAPY FAILUREAbabneh, H. S. / Ng, A. K. / Frigault, M. J. / Abramson, J. S. / Johnson, P. C. / Jacobson, C. A. / Patel, C. G. et al. | 2023
- 221
-
Review on natural killer/T‐cell lymphomaHe, Xiaohua / Gao, Yan / Li, Zhiming / Huang, Huiqiang et al. | 2023
- 222
-
BONE MARROW VOLUME IRRADIATED AND RISK OF CYTOPENIAS IN AGGRESSIVE B‐CELL LYMPHOMA PATIENTS BRIDGED WITH RADIATION THERAPY FOR CART CELL THERAPYManzar, G. S. / Dabaja, B. S. / Wu, S. Y. / Nasr, L. F. / Dudzinski, S. O. / Yoder, A. K. / Corrigan, K. L. / Gunther, J. R. / Ahmed, S. / Spiotto, M. et al. | 2023
- 223
-
IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCYMorschhauser, F. / Hatzi, K. / Lenz, G. / Herrera, A. F. / Flowers, C. R. / Trněný, M. / Burke, J. M. / Hou, J. / Staber, P. B. / Hawkes, E. A. et al. | 2023
- 225
-
SPATIALLY‐RESOLVED TRANSCRIPTOMICS DEFINE CLINICALLY RELEVANT SUBSETS OF MACROPHAGES IN DIFFUSE LARGE B‐CELL LYMPHOMALiu, M. / Bertolazzi, G. / Mulder, K. / Sridhar, S. / Tripodo, C. / Jeyasekharan, A. D. et al. | 2023
- 226
-
COORDINATED CHANGES IN THE TUMOR MICROENVIRONMENT (TME) ARE ASSOCIATED WITH INCREASED RISK OF THERAPEUTIC FAILURE IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)Soekojo, C. Y. / Whitaker, K. R. / Ferre, R. Leon / Moore, R. M. / Maurer, M. J. / Villasboas, J. C. et al. | 2023
- 228
-
EZH2 INHIBITION ENHANCES CAR T ANTITUMOR EFFECT BY INDUCING LYMPHOMA IMMUNOGENICITY AND ENHANCING T CELL FUNCTIONIsshiki, Y. / Porazzi, P. / Melnick, A. / Ruella, M. / Béguelin, W. et al. | 2023
- 228
-
SINGLE CELL ANALYSIS REVEALS IMMUNE DYSFUNCTION IN LARGE B CELL LYMPHOMA (LBCL) PTS WITH HYPOMAGNESEMIA RECEIVING AXI‐CEL: RESULTS FROM ZUMA‐1 TRIAL AND MAYO CLINIC COHORTMondello, P. / Gile, J. / Wang, Z. / Li, Y. / Bansal, R. / Gandhi, S. / Zhang, H. / Babadi, E. / Martinez, K. / McCoy, G. et al. | 2023
- 230
-
Elevated serum IL‐13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B‐cell lymphomaLi, Xiao / Liu, Mengke / Shi, Qing / Fang, Ying / Fu, Di / Shen, Zhi‐xiang / Yi, Hongmei / Wang, Li / Zhao, Weili et al. | 2023
- 230
-
FOLLICULAR LYMPHOMA PATIENT‐DERIVED ORGANOIDS FOR BISPECIFIC T‐CELL ENGAGER IMMUNOTHERAPYSchroers‐Martin, J. G. / Kastenschmidt, J. / Sworder, B. J. / Diehn, M. / Wagar, L. / Alizadeh, A. A. et al. | 2023
- 231
-
5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS)Ahn, I. E. / Brander, D. M. / Ren, Y. / Zhou, Y. / Tyekucheva, S. / Walker, H. A. / Black, R. / Montegaard, J. / Alencar, A. / Shune, L. et al. | 2023
- 233
-
LONG‐TERM FOLLOW‐UP OF MULTICENTER PHASE II TRIAL OF ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX (BOVEN) IN PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLLSoumerai, J. D. / Dogan, A. / Seshan, V. / Flaherty, K. / Carter, J. / Hochberg, E. / Barnes, J. A. / Abramson, J. S. / Hamilton, A. M. / Noy, A. et al. | 2023
- 235
-
ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDYShadman, M. / Munir, T. / Roback, T. / Brown, J. R. / Kahl, B. S. / Ghia, P. / Giannopoulos, K. / Šimkovič, M. / Österborg, A. / Laurenti, L. et al. | 2023
- 238
-
FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM THE FD COHORT OF THE PHASE 2 CAPTIVATE STUDYGhia, P. / Allan, J. N. / Siddiqi, T. / Wierda, W. G. / Tam, C. S. / Moreno, C. / Tedeschi, A. / Szafer‐Glusman, E. / Zhou, C. / Abbazio, C. et al. | 2023
- 239
-
Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysisLang, Mingxiao / Feng, Youqin / Meng, Xiangrui / Zhao, Jing / Song, Zheng / Qian, Zhengzi / Qiu, Lihua / Zhou, Shiyong / Liu, Xianming / Li, Lanfang et al. | 2023
- 239
-
MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)Kater, A. P. / Harrup, R. / Kipps, T. J. / Eichhorst, B. / Owen, C. J. / Assouline, S. / Lamanna, N. / Robak, T. / Serna, J. d. l. / Jaeger, U. et al. | 2023
- 243
-
Impact of the Affordable Care Act and Medicaid Expansion on Insurance Coverage and Outcomes in Patients with HIV‐associated Aggressive B‐cell Non‐Hodgkin LymphomasPremnath, N. / Reves, H. / Pandey, U. / Anderson, J. / Afrough, A. / Anderson, L. D. / Madanat, Y. F. / Collins, R. H. Jr / Chung, S. / Kaur, G. et al. | 2023
- 244
-
TESTICULAR LARGE B‐CELL LYMPHOMA IS GENETICALLY SIMILAR TO PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA AND DISTINCT FROM NODAL DIFFUSE LARGE B‐CELL LYMPHOMARivas‐Delgado, A. / López, C. / Clot, G. / Nadeu, F. / Grau, M. / Frigola, G. / Bosch, J. / Radke, J. / Ishaque, N. / Alcoceba, M. et al. | 2023
- 246
-
Subgrouping of Burkitt lymphoma variants by DNA methylation is driven by an EBV‐associated epigenotypeGlaser, S. / Del Val, C. / Wagener, R. / Kretzmer, H. / Klapper, W. / Hummel, M. / Ammerpohl, O. / Lichter, P. / Burkhardt, B. / Trümper, L. et al. | 2023
- 247
-
A transposable element atlas of aggressive B‐cell non‐Hodgkin lymphomas defines novel classifications of Burkitt lymphoma independent of EBV statusSingh, B. / Dopkins, N. / Fei, T. / Michael, S. / Marston, J. L. / Hernandez, M. M. A. / Heymann, J. J. / Chadburn, A. / Martin, P. / Leal, F. et al. | 2023
- 248
-
Characterization of the genetic and epigenetic landscape of B‐cell neoplasms with IG::BCL3‐translocationDrewes, C. / López, C. / Okeke, N. / Hillebrecht, S. / Schütz, P. / Fischer, A. / Mottok, A. / Bens, S. / Schneider, C. / Stilgenbauer, S. et al. | 2023
- 248
-
Genomic characterization of lymphomas in patients with inborn errors of immunityPan‐Hammarström, Q. et al. | 2023
- 248
-
Primary treatment and recent survival trends in patients with primary diffuse large B‐cell lymphoma of central nervous system, 1995–2016: A population‐based SEER analysisChen, Cui / Sun, Peng / Sun, Xiao‐Qing / Chen, Shao‐Yong / Hang Yang / Wang, Yu / Li, Zhi‐Ming et al. | 2023
- 249
-
Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head‐to‐Head Trial of Acalabrutinib Versus IbrutinibWoyach, J. A. / Jones, D. / Jurczak, W. / Robak, T. / Illés, A. / Kater, A. P. / Ghia, P. / Byrd, J. C. / Seymour, J. F. / Long, S. et al. | 2023
- 250
-
The RNA helicase DDX21 cooperates with ETS1 and FLI1 in cell cycle regulation and small nucleolar RNA processing to sustain the survival of DLBCL cellsSartori, G. / Priebe, V. / Cascione, L. / Favre‐Juilland, M. / Chung, E. Y. / Napoli, S. / Arribas, A. / Rinaldi, A. / Miazza, M. Thome / Bertoni, F. et al. | 2023
- 251
-
Alpha‐ketoglutarate Suppresses Tumor Growth of Diffuse Large B‐cell Lymphoma by Inducing FerroptosisCai, Y. / Lv, L. / Lu, T. / Ding, M. / Zhan, L. / Zhou, X. / Wang, X. et al. | 2023
- 253
-
CTPS1 acts as a prognostic biomarker and therapeutic target in mantle cell lymphomaLiang, J. / Ren, Y. / Du, K. / Wang, L. / Wang, R. / Li, J. / Xu, W. et al. | 2023
- 254
-
Lipid metabolism reprogramming roles in mantel cell lymphoma growth and survivalLiang, J. / Guo, J. / Du, K. / Shen, H. / Yin, H. / Wu, J. / Wang, L. / Li, J. / Xu, W. et al. | 2023
- 255
-
Deciphering the role of MSI2 as a regulator of stem‐like properties in mantle cell lymphomaAmador, V. / Sureda‐Gómez1, M. / Balsas, P. / Rodríguez, M. / De Bolòs, A. et al. | 2023
- 256
-
Lymph node location and retention properties of DC‐SIGN engagement with the Immunoglobulin Oligomannoses of Follicular LymphomaChiodin, G. / Tatterton, D. / Zhang, Y. / Duriez, P. / Ertay, A. / Rock, P. / del Rio, L. / Sale, B. / Lanham, S. / Stevenson, F. et al. | 2023
- 256
-
CD30 protects EBV‐positive diffuse large B‐cell lymphoma cells against mitochondrial dysfunction through increasing BNIP3 expressionLiang, J. / Wang, W. / Xing, T. / Guo, J. / Li, J. / Xu, W. et al. | 2023
- 257
-
Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphomaSong, Wenting / Chen, Zhan / Shi, Cunzhen / Gao, Yuyang / Feng, Xiaoyan / Li, Hongwen / Li, Zhaoming / Zhang, Mingzhi et al. | 2023
- 258
-
Activation of the Novel Tumor Suppressor SAMHD1 Inhibits Cell Growth and Induces Interferon‐beta (IFN‐β) Gene Expression in Classical Hodgkin Lymphoma (cHL)Xagoraris, I. / Stathopoulou, K. / Binh Nordentoft, C. An / Xyderou, P. / Kurzay, A. / Lundqvist, A. / Herold, N. / Rassidakis, G. et al. | 2023
- 258
-
Unraveling the mechanisms of c‐MYC‐mediated escape from antibody and T‐cell based anti‐tumor immune attack in B‐cell malignanciesde Jonge, V. / Csikós, T. / Eken, M. / Roemer, M. / Chamuleau, M. / Mutis, T. et al. | 2023
- 260
-
Deciphering the role of macrophages and T cells in primary central nervous system lymphoma: tumour aggressiveness and response to immunotherapiesPagès‐Geli, C. / Medina‐Gil, D. / Fernández‐Guzmán, P. / Hernández, C. / Crespo, M. et al. | 2023
- 261
-
The Immunobiology of histologic transformation in follicular lymphoma: a multi‐omic case‐control studySoekojo, C. Y. / Whitaker, K. R. / Ferre, R. Leon / Maurer, M. / Villasboas, J. C. et al. | 2023
- 262
-
Spatial transcriptomic profiling: The “Next Generation Diagnosis” distinguishing between EBV+ lymphoproliferations with Hodgkin‐like featuresPugh, M. R. / Fennell, E. / Leopold, G. / Murray, P. G. / Dojcinov, S. D. et al. | 2023
- 263
-
Combined single‐cell and spatially‐resolved mapping of lymph node ecosystems reveals principles of lymphoma tissue organizationCzernilofsky, F. / Mathioudaki, A. / Jopp‐Saile, L. / Lutz, R. / Vonficht, D. / Baertsch, M. / Vohringer, H. / Roider, T. / Ordoñez‐Rueda, D. / Pabst, C. et al. | 2023
- 264
-
Digital spatial profiling of the tumor microenvironment in Hodgkin‐like adult T‐cell leukemia/lymphomaTakeuchi, M. / Miyoshi, H. / Yamada, K. / Nakashima, K. / Sato, K. / Furuta, T. / Moritsubo, M. / Imamoto, T. / Arakawa, F. / Kouno, K. et al. | 2023
- 265
-
Single‐cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi‐Resistant proliferative drive CLL patientsSha, Y. / Qin, S. / Miao, Y. / Xia, Y. / Lu, X. / Dai, L. / Qiu, T. / Wu, W. / Fan, L. / Xu, W. et al. | 2023
- 266
-
Characterization of the tumor microenvironment in classic Hodgkin lymphoma: determining the deep immunophenotypic signature of T cells using mass cytometryNiu, A. / Whitaker, K. / Soekojo, C. Y. / Yang, Z. Z. / Kim, H. J. / Novak, A. J. / Ansell, S. M. / Villasboas, J. C. et al. | 2023
- 267
-
Clinical analysis of patients with primary and secondary extranodal natural killer/T‐cell lymphoma of central nervous systemLi, Xingying / Yu, Hui / Fu, Xiaorui / Zhang, Lei / Li, Xin / Li, Ling / Wang, Xinhua / Sun, Zhenchang / Zhang, Xudong / Li, Zhaoming et al. | 2023
- 267
-
Prognostic values of circulating TREM2+ and ARG1+ Mreg cells in adults with treatment‐naïve diffuse large B‐cell lymphomaWang, H. / Yang, F. / Yang, C. / Ko, P. / Li, C. / Liu, Y. / Tsai, C. / Liu, J. / Chen, P. / Chen, N. et al. | 2023
- 269
-
Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T‐cell lymphoma and cutaneous T‐cell lymphomaRoberts, N. L. / Lister, J. / Benani, N. N. / Jain, S. / Battaglia, T. / Abdelmalek, M. / Ayers, E. C. / Portell, C. / Williams, M. E. / Batchala, P. et al. | 2023
- 270
-
Genomic abnormalities involving class I HLA are common in advanced cutaneous T‐cell lymphomaKwang, A. C / Duran, G. E. / Li, S. / Torres, A. N. Bastidas / Herrera, M. / Wang, E. B. / Kurtz, D. M. / Kim, Y. H. / Khodadoust, M. S. et al. | 2023
- 272
-
T cell CD62L expression following nivolumab therapy is associated with response to rituximab‐nivolumab in treatment naïve follicular lymphoma: the 1st FLOR studyKoldej, R. M. / Barraclough, A. / Lee, S. T. / Morgan, H. / Holzwart, N. / Koshy, M. / Smith, C. / Chong, G. / Gilbertson, M. / Keane, C. et al. | 2023
- 272
-
RHOA deficiency drives decreased CD19 expression and immune dysregulation in CAR‐T resistant diffuse large B‐cell lymphomaNewsam, A. / Coughlin, C. / Goretsky, Y. / Sondhi, A. / Roberts, E. / Bilbao, D. / Ziccheddu, B. / Manera, P. / Maura, F. / Schatz, J. et al. | 2023
- 273
-
Shelter in place: Live CLL cells inside the bone marrow fibroblasts and its implication in drug resistanceWang, Y. L. / Vistarop, A. / Franzen, C. / Efimov, A. / Patel, P. / Lu, P. / Ma, S. / Cukierman, E. / Franco‐Barraza, J. / Gao, J. et al. | 2023
- 274
-
Degradation of CD47‐SIRPα axis by pomalidomide potentiates CD20 antibody‐dependent cellular phagocytosis against B‐cell lymphomaGuo, H. / Wang, H. / Yang, J. / Liu, Y. / Liu, X. / Zhang, Q. / Zhou, K. et al. | 2023
- 275
-
Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti‐CD19‐chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B‐cell lymphoma and high tumor burdenMu, Juan / Deng, Haobin / Lyu, Cuicui / Yuan, Jijun / Li, Qing / Wang, Jia / Jiang, Yanyu / Deng, Qi / Shen, Jichun et al. | 2023
- 275
-
Targeting monocytic‐myeloid suppressor cells through CSF1R‐blockade enhances CD19‐CAR T‐cell response in DLBCLGödel, P. / Stahl, D. / Riet, T. / Flümann, R. / Chmielewski, M. / Blakemore, S. / Segbers, P. / Tetenborg, L. / Reinhardt, H. C. / Borchmann, P. et al. | 2023
- 275
-
SAR442257, a CD38/CD28/CD3 trispecific antibody, potentiates CAR T‐cell activity against large B‐cell lymphomaGreen, M. R. / Reville, P. K. / Dai, E. / Sheikh, I. / Deng, Q. / Henderson, J. / Le, C. / Rojas, E. / Okwuchi, C. / Wilson, A. et al. | 2023
- 276
-
Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphomaTobin, J. W. / Tsang, H. / Patch, A. / Keane, C. / Law, S. C. / Gunawardana, J. / Blombery, P. / Thompson, E. R. / Sabdia, M. B. / De Long, L. M. et al. | 2023
- 277
-
Metabolic reprograming of exhausted intratumoral CD8+ T‐cell underlies anti‐tumor activity of SUMOylation inhibitors in Large B Cell LymphomaLownik, J. / Milshteyn, L. / Villamejor, A. L. / Merchant, A. A. et al. | 2023
- 278
-
Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapseSwain, F. / Burgess, M. / Kempe, S. / Sabdia, M. / Wight, J. / Hawkes, E. / Mutsando, H. / Talaulikar, D. / Merida de Long, L. / Hawula, Z. et al. | 2023
- 280
-
Itk inhibitor induces Th1 skewing and host anti‐tumor response mediated by CD8+ TEMRA cells in refractory T cell lymphoma patientsDing, N. / Xie, Y. / Miller, R. / Mahabhashyam, S. / Hsu, L. / Guo, Y. / Li, K. C. / Du, T. / Mi, L. / Lin, N. et al. | 2023
- 280
-
Enhancing T‐cell responses to GCB‐like lymphomas with immune‐checkpoint‐blockade‐based therapiesSerganova, I. / Bucktrout, R. / Isshiki, Y. / Sarapulov, A. / Santella, A. / Rodriguez, M. / Chakraborty, S. / Brunschvig, S. / Qualls, D. / Vardhana, S. et al. | 2023
- 281
-
Determinants of response to T‐cell stimulation by CD27 antibody therapy in lymphoma: The RiVa trialRose‐Zerilli, M. J. / Buermann, L. / Stanton, L. / Wignall, C. M. / Coleman, A. R. / Thorne, K. / Keyworth, N. / Konn, Z. / Turaj, A. H. / McKay, P. et al. | 2023
- 283
-
Gut microbiome in DLBCL patients undergoing first‐line R‐CHOP regimen—The Oncopassport StudyStefoni, V. / Argnani, L. / Casadei, B. / Musuraca, G. / Nanni, L. / Pellegrini, C. / Broccoli, A. / Carella, M. / Caldarulo, E. / Mammoli, F. et al. | 2023
- 285
-
Microbiota diversity in patients with Diffuse Large B‐Cell Lymphoma and Immune‐Privileged Sites LymphomaDlouha, L. / Tenglerova, M. / Rehakova, J. / Brichova, M. / Kostovcik, M. / Benesova, K. / Kverka, M. / Heissigerova, J. / Svozilkova, P. / Ondeckova, I. et al. | 2023
- 285
-
TAFRO syndrome with fatigue and abdominal distension as the first symptom: A case reportZhou, Bai / Tang, Chao / Chen, Guiyang / Jiang, Tiebin / Shi, Xiao / Wang, Fen et al. | 2023
- 286
-
TAyloring LYmphoma therapy with Immune Escape Signatures from 3D avatars of B‐cell NHLGava, F. / Faria, C. / Gravelle, P. / Garcia‐Valero, J. / Quelen, C. / Serrat, N. / Gower, N. / Morschhauser, F. / Fournié, J. / Bouquet, F. et al. | 2023
- 287
-
Study of the efficacy of novel bispecific antibodies targeting immune checkpoints in a 3D model of B non‐Hodgkin lymphomaGower, N. / Gava, F. / Rimailho, L. / Faria, C. / Gravelle, P. / Perez‐Galan, P. / Serrat, N. / Bouquet, F. / Fonseca, C. / Herter, S. et al. | 2023
- 288
-
Identification of an activated/memory B‐cell signature of poor outcome and sensitivity to lenalidomide in follicular lymphoma patientsLaurent, C. / Trisal, P. / Tesson, B. / Lesne, B. / Van‐Acker, N. / Chartier, L. / Stokes, M. / Huang, C. / Huet, S. / Morschhauser, F. et al. | 2023
- 290
-
A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trialMozas, P. / Ammar, R. Ould / Chartier, L. / Nastoupil, L. / Bachy, E. / Bezsera, S. M. / Barnes, J. / Bijou, F. / Goy, A. / Zerazhi, H. et al. | 2023
- 291
-
Genetic Alterations in Follicular Lymphoma Predict Response to Very Low Dose RadiotherapyWijetunga, N. A. / Lebow, E. / Chan, A. / Lee, J. / Fregonese, B. / Hajj, C. / Cedarquist, G. / Hubbeling, H. / Ma, J. / Sarkar, R. et al. | 2023
- 292
-
Proteomic profiling identifies apoptotic deregulation predictive of histological transformation in follicular lymphomaEnemark, M. B. H. / Sørensen, E. F. / Andersen, M. D. / Campbell, A. J. / Hybel, T. E. / Madsen, C. / Lauridsen, K. L. / F. d'Amore / Plesner, T. L. / Hamilton‐Dutoit, S. J. et al. | 2023
- 293
-
Richter transformation in Chronic Lymphocytic LeukemiaInnocenti, Idanna / Benintende, Giulia / Tomasso, Annamaria / Fresa, Alberto / Autore, Francesco / Larocca, Luigi Maria / Laurenti, Luca et al. | 2023
- 294
-
Impact of the Dark Zone Signature on Central Nervous System Relapse in a Real‐World Diffuse Large B‐cell Lymphoma PopulationAlduaij, W. / Jiang, A. / Collinge, B. / Ben‐Neriah, S. / Hilton, L. K. / Boyle, M. / Meissner, B. / Farinha, P. / Slack, G. / Villa, D. et al. | 2023
- 294
-
Assessment of Helicobacter pylori (HP) negative gastric MALT lymphoma for non‐H.pylori Helicobacter using multiplex PCR: a retrospective analysisRaderer, M. / Simonitsch‐Klupp, I. / Staudacher, M. / Hotz, J. / Kritz, R. / Schefberger, K. / Kiesewetter, B. / Lagler, H. et al. | 2023
- 296
-
Identification of biomarkers for predicting central nervous system involvement in patients with diffuse large B‐cell lymphomaPagès‐Geli, C. / Bobillo, S. / Abrisqueta, P. / Castellví, J. / Palomo, L. / Alvarez‐Errico, D. / Esteller, M. / Bosch, F. / Crespo, M. et al. | 2023
- 297
-
Predicting cell of origin from digitized images of hematoxylin and eosin‐stained slides of diffuse large B‐cell lymphomas using a cell‐based deep‐learning modelYüce, A. / Gildenblat, J. / Abbasi‐Sureshjani, S. / Laurent, C. / Korski, K. et al. | 2023
- 298
-
MYC negatively impacts treatment outcomes in stage II, but not stage I diffuse large B‐cell lymphomade Jonge, V. / Bult, J. / Karssing, D. / Nijland, M. / Chamuleau, M. / Brink, M. et al. | 2023
- 299
-
A sub‐population of cells expressing MYC and BCL2 without BCL6 refines the definition of double expressor lymphoma (DEL)Hoppe, M. M. / Sridhar, S. / Liu, M. / Jaynes, P. / Peng, Y. / Harris, C. III / Bottos, A. / Farinha, P. / Mottok, A. / Scott, D. W. et al. | 2023
- 300
-
Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitorShi, Z. / Fang, Y. / Xu, P. / Yi, H. / Li, J. / Dong, Y. / Zhu, Y. / Liu, M. / Fu, D. / Wang, S. et al. | 2023
- 301
-
Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancyCao, Han‐Yu / Li, Ling / Xue, Sheng‐Li / Dai, Hai‐Ping et al. | 2023
- 301
-
Biological and clinical relevance of CD79 protein and gene expression in diffuse large B‐cell lymphomaNaoi, Y. / Chijimatsu, R. / Urata, T. / Sunami, K. / Imai, T. / Nawa, Y. / Hiramatsu, Y. / Yamamoto, K. / Fujii, S. / Yoshida, I. et al. | 2023
- 302
-
Genetic and transcriptomic analyses of diffuse large B‐cell lymphoma patients with poor outcomes within two years of diagnosisRen, W. / Own, S. A. / Wan, H. / Berglund, M. / Wang, X. / Yang, M. / Li, X. / Liu, D. / Sonnevi, K. / Enblad, G. et al. | 2023
- 304
-
Genomic Correlates of Radiosensitivity in Diffuse Large B Cell LymphomaSarkar, R. R. / Ma, J. / Wijetunga, N. A. / Salles, G. / Joffe, E. / Imber, B. / Yahalom, J. et al. | 2023
- 305
-
Deep learning can predict presence of TP53 aberrations and IGHV mutational status from peripheral blood smears of chronic lymphocytic leukemiaPachong, S. Mebwe / Robrecht, S. / Ligtvoet, R. / Tausch, E. / Schneider, C. / Fürstenau, M. / von Tresckow, J. / Huber, H. / Stilgenbauer, S. / Cramer, P. et al. | 2023
- 306
-
Next Generation Sequencing in routine diagnostics of mature non‐Hodgkin’s lymphomas. A single‐center real‐life data studyBreinholt, M. F. / Schejbel, L. / Gang, A. O. / Nielsen, T. H. / Pedersen, L. M. / Høgdall, E. / Nørgaard, P. et al. | 2023
- 307
-
Machine Learning‐Based Stem Cell‐Like Phenotype Identification and Novel Risk Stratification in Diffuse Large B‐Cell Lymphoma: Multi‐Omics Data from Multicenter StudiesLiang, X. / Liang, Y. / Wang, X. / Jia, Y. / Young, K. H. / Feng, L. / Wang, L. et al. | 2023
- 309
-
LONG‐TERM FOLLOW‐UP AND GENE EXPRESSION PROFILES ASSOCIATED WITH OUTCOME IN PATIENTS WITH RELAPSED AGGRESSIVE B‐ OR T‐CELL LYMPHOMAS TREATED IN THE NORDIC P[R]EBEN TRIALRelander, T. / Leivonen, S. / Larsen, T. S. / Brown, P. / Jørgensen, J. M. / Mannisto, S. / Lugtenburg, P. / Holte, H. / Fagerli, U. M. / Lauritzsen, G. F. et al. | 2023
- 310
-
Interaction between gut microbiome and immune checkpoint inhibitor treatment in lymphoma patients: Final results of the MICRO‐LINF studyCasadei, B. / Argnani, L. / Guadagnuolo, S. / Nanni, L. / Pellegrini, C. / Broccoli, A. / Carella, M. / Stefoni, V. / Conti, G. / Turroni, S. et al. | 2023
- 310
-
TAFRO syndrome: A disease that known is half curedChen, Tingting / Feng, Chun / Zhang, Xinyou / Zhou, Jihao et al. | 2023
- 311
-
Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T‐cell Project 2.0.Manni, M. / Chiattone, C. S. / Prince, M. H. / Pavlovsky, A. / Tomuleasa, C. / Miranda, E. / Kriachok, I. / Hawkes, E. A. / Fiad, L. / Hitz, F. et al. | 2023
- 312
-
Angioimmunoblastic T cell lymphoma prognostic index in Asian population identifies low risk patients with unique gene expression profilesChang, E. W. Y. / Yang, V. S. / Ong, S. Y. / Lim, B. Y. / Mel, S. d. / Ng, E. K. / Poon, M. L. / Tan, Y. H. / Chang, J. / Poon, E. et al. | 2023
- 313
-
Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphomaPal, I. / Scotto, L. / Sabzevari, A. / Kinahan, C. / Fox, T. E. / Feith, D. J. / Marchi, E. / Loughran, T. P. Jr. / O'Connor, O. A. et al. | 2023
- 314
-
Serum Triglyceride and Apolipoprotein A1 as Biomarkers for Extranodal Natural Killer/T cell Lymphoma (ENKTL): A Multicenter StudyCai, Q. / Zhao, W. / Wang, L. / Li, Z. / Guo, H. / Wang, J. / Xiong, J. / Huang, H. / Xia, Y. / Tian, X. et al. | 2023
- 315
-
Soluble immune checkpoints HVEM and TIM‐3 are prognostic biomarkers for outcome in classical Hodgkin lymphomaFerdinandus, J. / Cirillo, M. / Bröckelmann, P. J. / von Tresckow, B. / Klapper, W. / Engert, A. / Borchmann, P. / Borchmann, S. et al. | 2023
- 316
-
A gene expression signature to predict disease progression for Hodgkin Lymphoma patients who achieve a complete metabolic response after 2 ABVD coursesDonati, B. / Nizzoli, M. E. / Durmo, R. / Ruffini, A. / Versari, A. / Merli, F. / Ciarrocchi, A. / Luminari, S. et al. | 2023
- 317
-
Deregulated hsa‐miR‐23a‐3p and hsa‐mir‐148a‐3p influence key processes in classic Hodgkin lymphoma (cHL) pathogenesisPaczkowska, J. / Janiszewska, J. / Ustaszewski, A. / Bein, J. / Skalski, M. / Schneider, M. / Bednarek, K. / Hansmann, M. / Dzikiewicz‐Krawczyk, A. / Rozwadowska, N. et al. | 2023
- 318
-
STING is Expressed by Hodgkin and Reed Sternberg (HRS) Cells in a Subset of Classical Hodgkin Lymphoma (cHL) and Correlates with Tumor Microenvironment and Immune ResponseXagoraris, I. / Mulder, T. / Stathopoulou, K. / Xyderou, P. / Andersson, M. / Palma, M. / Rassidakis, G. et al. | 2023
- 319
-
Proteomic profiling differentiates classic Hodgkin lymphoma with and without skeletal involvement at the time of diagnosisAndersen, M. D. / Enemark, M. B. / Pedersen, M. A. / Gormsen, L. C. / Lauridsen, K. L. / Starklint, J. / Hamilton‐Dutoit, S. J. / Ludvigsen, M. / d'Amore, F. A. / Honoré, B. et al. | 2023
- 319
-
Clinical utility of circulating tumor DNA qualification and quantification in classical Hodgkin lymphomaPirosa, M. C. / Bruscaggin, A. / Terzi di Bergamo, L. / Salehi, M. / Spina, V. / Pini, K. / Bocchetta, S. / Giordano, C. / Forestieri, G. / Condoluci, A. et al. | 2023
- 321
-
Distinct molecular determinants of treatment‐failure in elderly Hodgkin lymphoma identified by cell‐free DNA profiling: A LYSA StudyRossi, C. / Boegeholz, J. L. / Alig, S. K. / Garofolo, A. / Esfahani, M. Shahrokh / Schroers‐Martin, J. / Olsen, M. / Kang, X. / Kurtz, D. M. / Sugio, T. et al. | 2023
- 322
-
PET interim results could promptly select Follicular Lymphoma patients in need of maintenance therapy. Potential additional value of ctDNAJiménez‐Ubieto, A. / Poza, M. / López‐Pereira, P. / Figaredo, G. / Sarandeses, P. / Martin‐Muñoz, A. / Barrio, S. / Cortés, M. / Íñiguez, R. / Zamanillo, I. et al. | 2023
- 323
-
The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myelomaEseonu, Kelechi C. / Panchmatia, Jaykar R. / Streetly, Matthew J. / Grauer, Jonathan N. / Fakouri, Bahram et al. | 2023
- 323
-
Genetic characterization in tissue and cfDNA in marginal zone lymphomasDiez‐Feijóo, R. / Lafuente, M. / Garcia‐Gisbert, N. / Fernández‐Rodríguez, C. / Pinzón, S. / Sánchez‐González, B. / Gibert, J. / Fernández‐Ibarrondo, L. / Camacho, L. / Longarón, R. et al. | 2023
- 324
-
Serial circulating tumor DNA sequencing reveals clonal dynamics and can offer treatment guidance in relapsed/refractory diffuse large B‐cell lymphomaHeger, J. M. / Mattlener, J. / Schneider, J. / Schütte, D. / Gödel, P. / Becker, K. / Kutsch, N. / Balke‐Want, H. / Schwarz, R. F. / Reinhardt, H. C. et al. | 2023
- 326
-
Evaluation of ctDNA in a phase I/II trial in relapsed or refractory large B‐cell lymphoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T‐cell–engaging antibodySoong, D. / Thieblemont, C. / Karavitis, J. / Hess, B. / Caimi, P. / Feldman, T. / Hutchings, M. / Sureda, A. / Szafer‐Glusman, E. / Sacchi, M. et al. | 2023
- 328
-
Circulating tumour DNA concentration and genetic classification improve risk stratification in newly diagnosed patients with Diffuse Large B‐Cell LymphomaArzuaga‐Mendez, J. / Bilbao, N. / Lopez‐Lopez, E. / Rivas‐Delgado, A. / Enjuanes, A. / López‐Guillermo, A. / Amutio, E. / Martin‐Guerrero, I. / Garcia‐Ruiz, J. C. et al. | 2023
- 329
-
Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi‐cel) in large B‐cell lymphoma (LBCL)Miles, B. R. / Mao, D. / Vardhanabhuti, S. / To, C. / Schupp, M. / Shahani, S. / Xu, H. / Munoz, J. L. / Westin, J. / Shen, R. et al. | 2023
- 330
-
Clinical implications of ctDNA in predicting the genetic subtype, CNS involvement and outcomes of newly diagnosed diffuse large B cell lymphomaLiang, J. / Wu, Y. / Shen, H. / Yin, H. / Wu, J. / Li, Y. / Wang, L. / Li, J. / Xu, W. et al. | 2023
- 332
-
Molecular characterization of diffuse large‐B cell lymphoma by liquid biopsy at diagnosis and during follow‐up. OBO "Euroclonality‐NGS group" & "Grupo Colaborativo Linfomas y SLP de CyL"Alcoceba, M. / Stewart, J. P. / Álvarez, M. G. / Jiménez, C. / Medina, A. / Chillón, M. C. / Gazdova, J. / Blanco, Ó. / Díaz, L. G. / Villanueva, J. G. et al. | 2023
- 333
-
Personalized monitoring of circulating tumor DNA by a specific signature of trackable mutations after chimeric antigen receptor t‐cell therapy in non‐Hodgkin B cell lymphomaBastos, M. / Barrio, S. / Martin‐Muñoz, A. / de la iglesia, I. / Muñiz, P. / Dorado, S. / Bailen, R. / Poza, M. / Chicano, M. / Garcia‐Ortiz, A. et al. | 2023
- 334
-
LIQUID BIOPSY FOR EARLY, NON‐INVASIVE DIAGNOSIS OF EBV‐POSITIVE BURKITT LYMPHOMA IN RESOURCE LIMITED SETTINGSChamba, C. C. / Ntemi, P. / Schuh, A. / Cuts, A. / Balandya, E. / Vavoulis, D. / Dreau, H. / Burns, A. / Howard, K. / Rideout, K. et al. | 2023
- 335
-
Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patientsDerenzini, Enrico / Gueli, Angela / Risso, Alessandra / Bruna, Riccardo / Gottardi, Daniela / Cignetti, Alessandro / Pileri, Stefano / Avvedimento, Enrico V. / Tarella, Corrado et al. | 2023
- 335
-
Clinical impact of Epstein–Barr virus DNA in aggressive NK‐cell leukemiaFujimoto, A. / T., Maeda / Fukuhara, N. / Miyazaki, K. / Yamaguchi, M. / Ishida, F. / Suzuki, R. et al. | 2023
- 336
-
Molecular features possessed in the ctDNA reveal heterogeneity and predict outcome in newly diagnosed peripheral T‐cell lymphomaLiang, J. / Hua, W. / Shen, H. / Yin, H. / Wu, J. / Li, Y. / Wang, L. / Li, J. / Xu, W. et al. | 2023
- 338
-
Cell‐free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA studySako, N. / Delfau, M. / Bachy, E. / Morschhauser, F. / Cartron, G. / Casasnovas, O. / Gressin, R. / Daguindau, N. / Tournilhac, O. / Bouabdallah, K. et al. | 2023
- 339
-
The impact of spleen metabolic tumor volume on total metabolic tumor volume and prognosis in patients with follicular lymphoma enrolled in FOLL 12 trialGuerra, L. / Chauvie, S. / Marcheselli, L. / Bergesio, F. / Durmo, R. / Peano, S. / Franceschetto, A. / Fallanca, F. / Pinto, A. / Ghiggi, C. et al. | 2023
- 340
-
Comparison of machine learning approaches for POD24 prediction based on pretreatment PET in follicular lymphoma patients (on behalf of CALYM/LYSA groups)Hoang, D. T. / Schalck, E. / Ricci, R. / Chartier, L. / Marlot, L. / Gomez, E. / Nadel, B. / Xerri, L. / Morschhauser, F. / Kanoun, S. et al. | 2023
- 341
-
Automated FDG PET/CT radiomics for risk stratification in newly diagnosed diffuse large B‐cell lymphoma (DLBCL)Shreve, J. T. / Hazim, A. Z. / Bock, A. M. / Pritchett, J. C. / Maurer, M. J. / Shah, M. V. / Binder, M. / Witzig, T. E. / Wang, Y. / Nowakowski, G. S. et al. | 2023
- 342
-
An automated quantification algorithm for evaluating total metabolic tumor volume in patients with FDG‐avid lymphomas using a deep learning modelXu, T. / Jemaa, S. / Kumar, M. / Balasubramanian, S. / Shamas‐Din, A. / Lyalina, S. / Ounadjela, S. / Malik, B. / Lee, J. / Morales, S. Figueroa et al. | 2023
- 343
-
Impact of anti‐SARS‐CoV‐2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective studyAssanto, Giovanni Manfredi / Di Rocco, Alice / Malfona, Francesco / Capriata, Marcello / Del Giudice, Ilaria / Petrucci, Luigi / Girardi, Paola / D’Elia, Gianna Maria / Martelli, Maurizio / Gentile, Giuseppe et al. | 2023
- 344
-
Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory or early relapsing diffuse large B‐cell lymphoma (DLBCL)Bock, A. M. / Mwangi, R. / Ataei, F. / Thorpe, M. / Shreve, J. T. / Pritchett, J. C. / Maurer, M. J. / Paludo, J. / Cerhan, J. R. / Khurana, A. et al. | 2023
- 345
-
Differences in baseline PET/CT lymphoma distribution patterns between DLBCL‐NOS and high‐risk DLBCL patientsCroese, K. J. / Zwezerijnen, G. J. C. / Bes, A. L. / Wiegers, S. E. / Heymans, M. W. / Boellaard, R. / Lugtenburg, P. J. / Eertink, J. J. / Zijlstra, J. M. / Chamuleau, M. E. D. et al. | 2023
- 346
-
Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials—A LYSA retrospective analysisWillaume, A. / Chartier, L. / Ricci, R. / Blanc‐Durand, P. / Amorim, S. / Haioun, C. / Thieblemont, C. / Legouill, S. / Casasnovas, O. / Morschhauser, F. et al. | 2023
- 347
-
Modification of Lugano Criteria by Pre‐Infusion Tumor Kinetics Improves Early Survival Prediction for Lymphoma Patients Under Chimeric Antigen Receptor T‐Cell TherapyKunz, W. G. / Blumenberg, V. / Rejeski, K. / Buecklein, V. L. / Schmidt, C. / Dekorsy, F. J. / Bartenstein, P. / Ricke, J. / von Bergwelt‐Baildon, M. / Subklewe, M. et al. | 2023
- 349
-
Baseline PET Total Metabolic Tumor Volume has a prognostic role in PTCLs—Data from International Prospective T‐Cell Project 2.0Skrypets, T. / Chauvie, S. / Manni, M. / Fallanca, F. / Racca, M. / Hitz, F. / Advani, R. / Ramos, C. D. / Miranda, E. / Tomuleasa, C. et al. | 2023
- 349
-
Interim 3‐Dimensional volumetric response (3DVR) is associated with better overall survival of patients (pts) with primary central nervous system lymphoma (PCNSL)Martynchyk, A. / O'Shaughnessy, J. / Lee, S. / Chong, G. / Agrawal, S. / Tatarczuch, M. / Narisa, A. Azryn / Gregory, G. P. / Churilov, L. / Hawkes, E. A. et al. | 2023
- 350
-
Baseline‐PET derived metrics are the most relevant factors for risk stratification in early‐stage nonbulky HL: preliminary results of the RAFTING trialZaucha, J. M. / Picardi, M. / Kurlapski, M. / Patti, C. / Domingo‐Domenech, E. / Sanz, R. Garcia / Rossi, A. / Lopez‐jimenez, J. / Trentin, L. / Gotti, M. et al. | 2023
- 351
-
PET‐Adapted Therapy with Nivolumab plus Adriamycin, Vinblastine, and Dacarbazine for Newly Diagnosed Stage III or IV Hodgkin LymphomaMoskowitz, A. / Savage, K. / Feldman, T. / Ganesan, N. / Hancock, H. / Davey, T. / Perez, L. / Santarosa, A. / Subzwari, S. / Capadona, C. et al. | 2023
- 353
-
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early‐stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35‐027 Part C)Abramson, J. S. / Straus, D. / Bartlett, N. / Burke, J. M. / Lynch, R. C. / Domingo‐Domenech, E. / Hess, B. / Schuster, S. / Linhares, Y. / Ramchandren, R. et al. | 2023
- 354
-
Risk of a second cancer and infection in patients with indolent B‐cell lymphoma exposed to first‐line bendamustine plus rituximab: A retrospective analysis of an administrative claims databaseDote, Satoshi / Inose, Ryo / Goto, Ryota / Kobayashi, Yuka / Muraki, Yuichi et al. | 2023
- 355
-
Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 studyFerdinandus, J. / Müller, H. / Damaschin, C. / Jacob, A. S. / Meissner, J. / Krasniqi, F. / Mey, U. / Schöndube, D. / Thiemer, J. / Mathas, S. et al. | 2023
- 356
-
Replacing procarbazine with dacarbazine in escalated BEACOPP reduces clinical toxicity with no loss of efficacy yet protects stem cells from excess somatic mutational damageSantarsieri, A. / Mitchell, E. / Sanghvi, R. / Lee‐Six, H. / Sturgess, K. / Brice, P. / Menne, T. / Osborne, W. / Creasey, T. / Ardesnhna, K. M. et al. | 2023
- 357
-
‘ACOPP’ chemotherapy for older and less fit patients with Hodgkin lymphoma—a multicentre, retrospective studyWilson, M. R. / Haynes, E. / Hopkins, D. / Robertson, E. / Parsons, K. / Ferguson, G. / Quinn, D. / Murray, J. / Osborne, W. / Leach, M. et al. | 2023
- 359
-
Brentuximab vedotin (BV) + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): incidence and management of peripheral neuropathy (PN) in a multi‐institution cohortBowers, J. T. / Anna, J. / Bair, S. M. / Annunzio, K. / Epperla, N. / Pullukkara, J. Joy / Gaballa, S. / Spinner, M. / Li, S. / Messmer, M. et al. | 2023
- 360
-
BEGEV as salvage regimen in first setting for relapsed/refractory classical Hodgkin lymphomaCarella, M. / Argnani, L. / Coppola, P. E. / Nanni, L. / Zoli, S. / Cantelli, M. / Morigi, A. / Gentilini, M. / Lolli, G. / Bagnato, G. et al. | 2023
- 361
-
Efficacy of brentuximab consolidation by metabolic response in an international real‐world cohort of classic Hodgkin lymphoma at high risk for progression after ASCTDesai, S. H. / Smith, A. / Spinner, M. / Sykorova, A. / Bachanova, V. / Evens, A. M. / Goyal, G. / Kahl, B. / Dorritie, K. / Azzi, J. et al. | 2023
- 363
-
Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective studyMattiello, Veronica / Barone, Angelica / Giannarelli, Diana / Noto, Alessandro / Cecchi, Nicola / Rampi, Nicolò / Cassin, Ramona / Reda, Gianluigi et al. | 2023
- 363
-
Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study GroupFerdinandus, J. / Moccia, A. A. / Greil, R. / Hertzberg, M. / Schaub, V. / Hüttmann, A. / Keil, F. / Dierlamm, J. / Hänel, M. / Novak, U. et al. | 2023
- 364
-
Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma—Polish Lymphoma Research Group StudyPaszkiewicz‐Kozik, E. / Kurlapski, M. / Swoboda, R. / Subocz, E. / Szymanski, M. / Taszner, M. / Wicherska‐Pawlowska, K. / Koclega, A. / Domanska‐Czyz, K. / Swierkowska, M. et al. | 2023
- 364
-
An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatmentLavie, D. / Johnson, N. / Borchmann, P. / Herrera, A. F. / Avigdor, A. / Gasiorowski, R. / Gregory, G. / Keane, C. / Vucinic, V. / Bazargan, M. et al. | 2023
- 366
-
Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agentsDesai, S. H. / Spinner, M. / Evens, A. M. / Bachanova, V. / Goyal, G. / Kahl, B. / Dorritie, K. / Azzi, J. / Kenkre, V. P. / Arai, S. et al. | 2023
- 368
-
Role of autologous stem cell transplantation or salvage chemotherapy in relapsed/refractory classical Hodgkin lymphoma patients after immune checkpoint inhibitorsPellegrini, C. / Casadei, B. / Sutto, E. / Cantelli, M. / Argnani, L. / Broccoli, A. / Gugliotta, G. / Stefoni, V. / Nanni, L. / Carella, M. et al. | 2023
- 369
-
Secondary cancer is the leading cause of death 15 years or more after diagnosis of early‐stage Hodgkin lymphomaLagerlöf, I. / Fohlin, H. / Enblad, G. / Glimelius, B. / Goldkuhl, C. / Palma, M. / Glimelius, I. / Molin, D. et al. | 2023
- 370
-
Overall survival and causes of death in elderly patients with Hodgkin lymphoma—a Norwegian population‐based case‐control studyLia, K. / Jørgensen, R. R. K. / Wold, B. L. / Fluge, Ø. / Fagerli, U. / Bersvendsen, H. / Bø, I. B. / Bhargava, S. / Fosså, A. et al. | 2023
- 371
-
Malnutrition diagnosed by GLIM criteria better predicts long‐term outcomes for patients with non‐Hodgkin's lymphoma: A prospective multicenter cohort studyZou, Yuanlin / Xu, Hongxia / Lyu, Quanjun / Weng, Min / Cui, Jiuwei / Shi, Hanping / Song, Chunhua et al. | 2023
- 371
-
Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphomaGao, F. / Liu, H. / Wang, X. / Zhang, H. et al. | 2023
- 372
-
Real‐world treatment patterns and clinical outcomes among follicular lymphoma patients in the SEER‐Medicare populationChihara, D. / Yang, S. / Chawla, S. Bains / Zhang, G. / Wang, A. / Yu, J. / Arnette, D. / Navarro, F. Rivas / Blaedel, J. / Mutebi, A. et al. | 2023
- 373
-
Analysis of Real‐World Treatment Patterns and Outcomes Among Patients With Relapsed/Refractory Follicular Lymphoma Including POD24 PatientsSehn, L. H. / Wang, A. / Yu, J. / Kamalakar, R. / Sail, K. / Sinai, W. / Arnette, D. / Yang, S. / Mutebi, A. / Navarro, F. R. et al. | 2023
- 375
-
Real‐World Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory (R/R) Follicular Lymphoma (FL)Jacobson, C. / Hemmer, M. T. / Hu, Z. / Frank, M. / Popplewell, L. / Ahmed, N. / Lin, Y. / Best, T. / Beygi, S. / Miao, H. et al. | 2023
- 376
-
The prognostic value of progressing within 24 months of frontline chemoimmunotherapy (POD24) in relapsed/refractory (R/R) follicular lymphoma (FL)—a SCHOLAR‐5 analysisPatel, A. R. / Limbrick‐Oldfield, E. H. / Kanters, S. / Ray, M. D. / Best, T. / Ghione, P. / Neelapu, S. S. / Gribben, J. G. / Beygi, S. / Bobillo, S. et al. | 2023
- 378
-
Prognostic value of the end of induction PET in patients with follicular lymphoma: results from the analysis of FOLL 12 trialGuerra, L. / Bergesio, F. / Fallanca, F. / Chauvie, S. / Marcheselli, L. / Durmo, R. / Peano, S. / Franceschetto, A. / Pinto, A. / Tani, M. et al. | 2023
- 378
-
Treatment outcomes of Limited Stage Grade 3A Follicular LymphomaSarkar, R. R. / Lee, J. / Zhang, Z. / Zelenetz, A. / Salles, G. / Yahalom, J. / Imber, B. et al. | 2023
- 380
-
Prognostic value of prognostic nutritional index on extranodal natural killer/T‐cell lymphoma patients: A multicenter propensity score matched analysis of 1022 cases in Huaihai Lymphoma Working GroupShen, Ziyuan / Zhang, Shuo / Chen, Xicheng / Zhang, Qing / Jiao, Yaxue / Shi, Yuye / Zhang, Hao / Ye, Jingjing / Wang, Ling / Zhu, Taigang et al. | 2023
- 380
-
Outcomes in primary gastrointestinal (GI) follicular lymphoma (FL): results from a multicenter analysisSt‐Pierre, F. / Alrifai, T. / Alhamad, K. / McCall, B. / Annunzio, K. / Mi, X. / Doukas, P. G. / Schoen, A. / Fu, L. / Au, C. et al. | 2023
- 381
-
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular LymphomaUjjani, C. / Wang, H. / Broome, C. / Gopal, A. / Lai, C. / Warren, E. / Shadman, M. / Smith, S. D. / Lynch, R. / Swanson, N. et al. | 2023
- 383
-
A Phase II Investigator Initiated Study of Acalabrutinib, Lenalidomide and Rituximab (aR2) in Patients with Previously Untreated High Tumor Burden Follicular LymphomaStrati, P. / Feng, L. / Westin, J. / Nair, R. / Gouni, S. / Fayad, L. / Rodriguez, M. / Chihara, D. / Malpica, L. / Steiner, R. et al. | 2023
- 383
-
Outpatient administration of mosunetuzumab in US community practice settings: perspectives and learnings from the Phase II MorningSun studyFlinn, I. W. / Sharman, J. / Liu, S. / Gandhi, M. / Anz, B. / Biondo, J. M. L. / Jani, P. / Wu, M. / Lin, T. / Parmar, N. et al. | 2023
- 385
-
The impact of CHOP versus bendamustine on bone mineral density in patients with follicular lymphoma enrolled in the GALLIUM studyPedersen, M. A. / Gormsen, L. C. / Jakobsen, L. H. / Eyre, T. A. / Severinsen, M. T. / Baech, J. / Dann, E. J. / Knapp, A. / Sahin, D. / Vestergaard, P. et al. | 2023
- 386
-
Evaluation of the GELTAMO guidelines for surveillance in follicular lymphomas after first‐line immunochemotherapy: a real‐world prospective studyLlodrà, M. A. / Marino, S. F. Pinzón / Díez‐Feijoo Varela, R. / Lafuente, M. / Sánchez‐González, B. / Maiques, J. M. / Silvestre, A. Salar et al. | 2023
- 387
-
REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real‐world prospective cohort.Bommier, C. / Donzel, M. / Rossi, C. / Fornecker, L. / Bijou, F. / Chauchet, A. / Lebras, L. / Ysebaert, L. / Haioun, C. / Bouabdallah, K. et al. | 2023
- 388
-
Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)Thieblemont, C. / Wang, K. / Keeping, S. / Zhang, I. / Yang, K. / Tang, B. / Mohseninejad, L. et al. | 2023
- 389
-
Lenalidomide treatment for recurrent adult T‐cell leukemia/lymphoma after allogeneic hematopoietic cell transplantationTanaka, Takashi / Inamoto, Yoshihiro / Ito, Ayumu / Watanabe, Mizuki / Takeda, Wataru / Aoki, Jun / Kim, Sung‐Won / Fukuda, Takahiro et al. | 2023
- 389
-
Orelabrutinib, a new‐generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphomaSong, Y. / Li, Z. / Zhang, H. / Liu, L. / Hu, J. / Huang, H. / Liu, T. / Jin, J. / Li, W. / Huang, Z. et al. | 2023
- 390
-
Long‐term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB‐3111‐214) trialTrotman, J. / Tedeschi, A. / Hu, B. / Linton, K. M. / McKay, P. / Leitch, S. / Jin, J. / Sun, M. / Sobieraj‐Teague, M. / Zinzani, P. L. et al. | 2023
- 393
-
A single‐center experience of low‐dose radiotherapy for primary extranodal marginal zone lymphoma of bronchus‐associated lymphoid tissue (BALT)Freret, M. E. / Tringale, K. R. / Imber, B. S. / Joffe, E. / Yahalom, J. / Hajj, C. et al. | 2023
- 394
-
CLinicopathological characteristics of extranodal marginal zone B‐cell lymphoma of the intestine: a single center analysisSteinbrecher, O. / Kiesewetter, B. / Dolak, W. / Simonitsch‐Klupp, I. / Raderer, M. et al. | 2023
- 394
-
Autologous and allogeneic stem‐cell transplantation for transformed Waldenström macroglobulinemiaDurot, E. / Kanagaratnam, L. / Zanwar, S. / Kaufman, A. / D'Sa, S. / Toussaint, E. / Roos‐Weil, D. / Alcoceba, M. / Vos, J. M. / Hivert, B. et al. | 2023
- 396
-
Efficacy and safety of PD‐1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective studyTian, Jing / Hao, Miaowang / Liu, Qiang / Xiao, Fang / Li, Yuanchun / Qi, Meiying / Gao, Jing / Liu, Li / Yin, Dandan et al. | 2023
- 396
-
Indolent lymphoma: Bendamustine, rituximab and acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM)Berinstein, N. L. / Roos, K. / Klein, G. / McClure, R. / Forward, N. / Shafey, M. / Nikonova, A. / MacDonald, D. / Villa, D. / Sandhu, I. et al. | 2023
- 397
-
Single‐agent rituximab as an effective salvage therapy in pre‐treated hairy cell leukemiaBroccoli, A. / Argnani, L. / Nanni, L. / Lolli, G. / Stefoni, V. / Zoli, S. / Cantelli, M. / Pellegrini, C. / Morigi, A. / Gentilini, M. et al. | 2023
- 397
-
Intralesional rituximab in the treatment of primary cutaneous B‐cell lymphomas: a single‐center experienceRampi, N. / Muniesa, C. / Pereira, P. Lopez / Climent, F. / Frias‐Gomez, J. / Barca, E. Gonzalez / Oliveira, A. C. / Aguilera, C. / Sureda, A. / Servitje, O. et al. | 2023
- 399
-
Patterns of disease failure by response to induction therapy in a large cohort of patients with primary central nervous system lymphomaTringale, K. R. / Yahalom, J. / Scordo, M. / White, C. / Zhang, Z. / Grommes, C. / Imber, B. et al. | 2023
- 400
-
Ibrutinib in Combination with Ifosfamide, Etoposide, and Rituximab Followed by Ibrutinib Maintenance Therapy in Patients with R/R‐PCNSL: A Multicenter Phase II StudyChoi, Y. S. / Song, G. / Baek, D. W. / Yoon, S. E. / Kang, K. / Yhim, H. / Oh, S. Y. / Jeong, S. H. / Kim, S. J. / Kim, H. J. et al. | 2023
- 401
-
Evolving consolidation patterns and modern outcomes for a large longitudinal cohort of primary CNS lymphoma patientsImber, B. S. / Tringale, K. / White, C. / Zhang, Z. / Scordo, M. / Yahalom, J. / Grommes, C. et al. | 2023
- 401
-
Induction (MATRix) Followed by Transplantation in Primary Central Nervous System Lymphoma. Experience of the GELTAMO (Grupo Español de Linfoma y Trasplante de Medula Ósea)Lopez‐Pereira, P. / Romero‐Dominguez, S. / Martin‐Moro, F. / Caballero‐Gonzalez, A. C. / Lopez‐Garcia, A. / Cruz‐Benito, B. de la / Franch‐Sarto, M. / Cruz‐Vicente, F. de la / Lopez‐Marin, J. / Pinzon‐Marino, S. et al. | 2023
- 403
-
Bone Marrow Assessment may be Omitted in Newly Diagnosed Diffuse Large B‐Cell Lymphomas with Primary CNS InvolvementMartin‐Moro, F. / Lopez‐Pereira, P. / Marquet‐Palomanes, J. / Bento, L. / Salar, A. / Sancho, J. M. / Gonzalez‐Villambrosia, S. / Lario‐Arribas, A. / Sanchez‐Pina, J. M. / Garcia, D. et al. | 2023
- 404
-
Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphomaYi, J. H. / Kim, S. J. / Yang, D. / Do, Y. R. / Won, J. H. / Baek, D. / Shin, H. J. / Kim, D. S. / Kim, H. J. / Kang, K. et al. | 2023
- 405
-
Preliminary results of penpulimab combined with RMA (rituximab, methotrexate, and cytarabine) for newly diagnosed primary central nervous system lymphoma (PCNSL)Shen, H. / Wu, J. / Liang, J. / Yin, H. / Wang, L. / Li, J. / Xu, W. et al. | 2023
- 406
-
Radiotherapy as an effective bridge for chemo‐refractory or progressive secondary CNS lymphomaCederquist, G. / Tringale, K. / Hajj, C. / Hubbeling, H. / Sarkar, R. / Ma, J. / Dreyfuss, A. / Fregonese, B. / Lee, J. / Salles, G. et al. | 2023
- 407
-
Geriatric assessment scores: Predictors of prognosis and premature end of treatment in the MARTA and MARiTA study population of elderly PCNSL patients >65 yearsIsbell, L. K. / Vreden, A. / Ihorst, G. / Uibeleisen, R. / Friedl, A. / Orban, A. / Malenica, N. / Fricker, H. / Wendler, J. / Neumaier, S. et al. | 2023
- 407
-
Long‐term outcomes in Hodgkin lymphoma survivors. Temporary trends and comparison with general populationNúñez‐García, Beatriz / Clemente, Mariola Blanco / Sánchez, Juan Cristóbal / Royuela, Ana / Ibargüen, Blanca Cantos Sánchez de / Méndez, Miriam / López‐Ibor, Jorge V. / Martínez, Marta / Traseira, Cristina / Garitaonaindia, Yago et al. | 2023
- 408
-
Primary Mediastinal B‐cell Lymphoma, a nationwide real‐life retrospective study from Fondazione Italiana Linfomi (FIL)Iannitto, E. / Balzarotti, M. / Martelli, M. / Zinzani, P. / Tucci, A. / Di Rocco, A. / Cavallo, F. / Usai, S. V. / Guidetti, A. / Ravano, E. et al. | 2023
- 410
-
REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTSVassilakopoulos, T. / Ferhanoglu, B. / Horowitz, N. / Mellios, Z. / Kaynar, L. / Zektser, M. / Symeonidis, A. / Piperidou, A. / Giotas, A. / Agathocleous, A. et al. | 2023
- 411
-
Axicabtagene ciloleucel (Axicel) for relapsed/refractory primary mediastinal B‐cell lymphoma (r/r PMBCL) compared to DLBCL‐NOS: A GLA/DRST registry study.Schubert, M. / Ayuk, F. A. / Bethge, W. / von Bonin, M. / Vucinic, V. / Wagner‐Drouet, E. M. / Subklewe, M. / Baldus, C. D. / Glass, B. / Marks, R. et al. | 2023
- 412
-
Primary lymphoma of the female genital tract: a retrospective survey of the International Extranodal Lymphoma Study Group (IELSG35)Steffanoni, S. / Vanazzi, A. / Esposito, F. / Cabrera, M. E. / Akhtar, S. S. / Gardella, S. / Bairey, O. / Pavlovsky, A. / Polino, A. / Landi, F. et al. | 2023
- 413
-
Comparison Between aaIPI, LAB‐PI, NCCN‐IPI and GELTAMO‐IPI to Predict Prognosis in Elderly Patients with Diffuse Large‐B Cell Lymphoma who Undergo R‐CHOP/R‐miniCHOPMartin‐Moro, F. / Marquet‐Palomanes, J. / Bento, L. / Diaz‐Lopez, A. / Garcia‐Vela, J. A. / Sanchez‐Pina, J. M / Cordoba, R. / Salar, A. / Novelli, S. / Rodriguez‐Salazar, M. J. et al. | 2023
- 414
-
Patient‐ versus clinician‐reported symptoms in the POLARIX studyThompson, C. A. / Mehta‐Shah, N. / Flowers, C. / Salles, G. / Tilly, H. / Chua, N. / Casasnovas, R. / Miall, F. / Kim, T. M. / Tsai, C. et al. | 2023
- 415
-
Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trialBiggi, Alberto / Chauvie, Stephane / Fallanca, Federico / Guerra, Luca / Bergesio, Fabrizio / Menga, Massimo / Bianchi, Andrea / Gregianin, Michele / Chiaravalloti, Agostino / Schillaci, Orazio et al. | 2023
- 416
-
Subgroup analysis of elderly patients (pts) with diffuse large B‐cell lymphoma (DLBCL) in the Phase 3 POLARIX studyHu, B. / Reagan, P. M. / Sehn, L. H. / Sharman, J. / Hertzberg, M. / Zhang, H. / Kim, A. / Herbaux, C. / Molina, L. / Maruyama, D. et al. | 2023
- 418
-
A Retrospective Analysis of Clinical Characteristics, Treatment, and Outcomes in Large B‐cell Lymphomas with Synchronous Systemic and Central Nervous System InvolvementHaydu, J. E. / Redd, R. A. / Lei, M. / Karschnia, P. / Dietrich, J. M. / Nayak, L. / Abramson, J. S. et al. | 2023
- 420
-
Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphomaLenz, G. / Tilly, H. / Ziepert, M. / Altmann, B. / Craine, V. / Yan, M. / Herbaux, C. / Frontzek, F. / Nickelsen, M. / Hirata, J. et al. | 2023
- 421
-
Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITIONMinson, A. / Verner, E. / Giri, P. / Wong, S. M. / Ratnasingam, S. / Butler, J. / Janowski, W. / Ku, M. / Cheah, C. Y. / Hertzberg, M. et al. | 2023
- 422
-
Zanbrutinib, lenalidomide plus R‐CHOP (ZR2‐CHOP) as the first‐line treatment for non‐GCB diffuse large B‐cell lymphoma: An updated analysis of efficacy and tolerabilityZhu, H. / Xia, Y. / Sha, Y. / Miao, Y. / Qin, S. / Wu, W. / Ding, C. / Wang, Z. / Fan, L. / Xu, W. et al. | 2023
- 424
-
Ibrutinib + bortezomib + R‐CHOP for higher‐risk DLBCL: Feasibility, efficacy and molecular predictorsDenker, S. / Bittner, A. / Frick, M. / Kase, J. / Hoffmann, J. / Trenker, C. / Keller, U. / Bogner, C. / Hüttmann, A. / Dürig, J. et al. | 2023
- 424
-
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide‐treated myeloma patientsAsano, Arisa / Ri, Masaki / Masaki, Ayako / Maeda, Yasuhiro / Tachita, Takuto / Hirade, Kentaro / Marumo, Yoshiaki / Nakashima, Takahiro / Hagiwara, Shinya / Kinoshita, Shiori et al. | 2023
- 425
-
Pixantrone containing R‐CPOP as firstline treatment in elderly DLBCL patients with congestive heart failure or high risk of anthracycline induced cardiotoxicityMarks, R. / Lorenz, K. / Trepel, M. / Rank, A. / Illerhaus, G. / Pelz, H. / Scholz, C. / Duyster, J. / Strüßmann, T. et al. | 2023
- 426
-
Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCLVerner, E. / Johnston, A. / Pati, N. / Hawkes, E. / Lee, H. P. / Cochrane, T. / Cheah, C. Y. / Filshie, R. / Purtill, D. / Sia, H. et al. | 2023
- 427
-
The treatment of Burkitt lymphoma with the Berlin‐Frankfurt‐Münster protocol with rituximab and autologous transplantationBroccoli, A. / Argnani, L. / Gugliotta, G. / Stefoni, V. / Pellegrini, C. / Casadei, B. / Nanni, L. / Coppola, P. E. / Sutto, E. / Cantelli, M. et al. | 2023
- 428
-
Quality of life and response shift effect of diffuse large B‐cell lymphoma French patients included in prospective real‐life REALYSA cohort in the first year after diagnosisAnota, A. / Basset, M. / Belot, A. / Bascoul‐Mollevi, C. / Cottone, F. / Efficace, F. / Préau, M. / Touraine, C. / Damaj, G. / Guidez, S. et al. | 2023
- 429
-
Trends in relative survival of Diffuse large B‐cell lymphoma in Sweden in the era of targeted and cellular therapiesSmedby, K. Ekström / Antonilli, S. / Enblad, G. / Sonnevi, K. / Wahlin, B. E. / Andersson, P. / Jerkeman, M. / Eloranta, S. et al. | 2023
- 430
-
Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival OutcomesBock, A. M. / Mwangi, R. / Wang, Y. / Khurana, A. / Maurer, M. J. / Ayers, A. / Kahl, B. / Martin, P. / Cohen, J. / Casulo, C. et al. | 2023
- 432
-
Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: Descriptive analysis of POLARIXHerbaux, C. / Dietrich, S. / McMillan, A. / Thieblemont, C. / Gonzalez‐Barca, E. / Pinto, A. / Fogliatto, L. / Matasar, M. / Lee, C. / Hernandez, J. et al. | 2023
- 433
-
Comparison of clinical outcomes in patients with relapsed/refractory large B‐cell lymphoma treated with epcoritamab versus chemoimmunotherapyIp, A. / Rosenthal, A. / Mutebi, A. / Wang, T. / Jun, M. / Wang, A. / Yu, J. / Brodkin, S. / Sacchi, M. / Kalsekar, A. et al. | 2023
- 434
-
Novel therapies for the treatment of relapsed‐refractory aggressive B‐cell lymphoma increase survival. Analysis from the RELINF registry of the GELTAMO groupBastos‐Oreiro, M. / Abrisqueta, P. / Gutierrez, A. / Jimenez‐Ubieto, A. / Gonzalez de Villambrosia, S. / Córdoba, R. / López, A. / Poza, M. / Ceballos, E. Pérez / Navarro, B. et al. | 2023
- 434
-
Diagnostic relevance of 2‐[18F]‐FDG PET/CT in patients recently diagnosed with monoclonal gammopathy of undetermined significanceRudolphi‐Solero, Teodoro / Triviño‐Ibáñez, Eva María / González‐Jiménez, Antonio Daniel / Ramos‐Font, Carlos / Ríos‐Tamayo, Rafael / Rebollo‐Aguirre, Angel Custodio / Sánchez‐Sánchez, Rocío et al. | 2023
- 436
-
Venetoclax combined with R‐ICE (VICER) for second line treatment of diffuse large B cell lymphoma refractory or relapsed after initial chemoimmunotherapyCaimi, P. F. / Cashen, A. / Gallogly, M. / Winter, A. / Boughan, K. / Ghobadi, A. / Jagadeesh, D. / Cooper, B. / Mehta‐Shah, N. / Dean, R. et al. | 2023
- 437
-
Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR)Fornecker, L. / Delwail, V. / Thieblemont, C. / Ghesquieres, H. / Bouabdallah, K. / Tilly, H. / Le Calloch, R. / Morschhauser, F. / Costello, R. / Slama, B. et al. | 2023
- 437
-
Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND studyDuell, J. / Abrisqueta, P. / Andre, M. / Augustin, M. / Gaidano, G. / Barca, E. G. / Jurczak, W. / Kalakonda, N. / Liberati, A. M. / Maddocks, K. J. et al. | 2023
- 439
-
Five‐year subgroup analysis of tafasitamab + lenalidomide from the Phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphomaDuell, J. / Abrisqueta, P. / Dreyling, M. / Gaidano, G. / Barca, E. G. / Jurczak, W. / Maddocks, K. J. / Menne, T. / Nagy, Z. / Tournilhac, O. et al. | 2023
- 441
-
Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND)Sehn, L. H. / Kuruvilla, J. / Salles, G. / Maddocks, K. J. / Koch, C. / Xue, Z. / Amoloja, T. / Amin, A. / Duell, J. et al. | 2023
- 442
-
Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs studySunami, Kazutaka / Fuchida, Shin‐ichi / Suzuki, Kenshi / Ri, Masaki / Matsumoto, Morio / Shimazaki, Chihiro / Asaoku, Hideki / Shibayama, Hirohiko / Ishizawa, Kenichi / Takamatsu, Hiroyuki et al. | 2023
- 443
-
Interim report from a phase 2 multicenter study of anti‐PD‐1 antibody (penpulimab) plus lenalidomide, rituximab, gemcitabine and oxaliplatin in Relapsed/ Refractory DLBCLLiang, J. / Wang, F. / Shen, H. / Yin, H. / Wu, J. / Li, Y. / Wang, L. / Li, J. / Gu, W. / Xu, W. et al. | 2023
- 443
-
Combination of acalabrutinib with rituximab and lenalidomide in relapsed/refractory B cell non‐Hodgkin lymphomaPark, C. / Lee, H. S. / Kang, K. / Lee, W. / Do, Y. R. / Kwak, J. / Shin, H. / Kim, S. / Yi, J. H. / Lim, S. N. et al. | 2023
- 445
-
Predictors of long‐term survival outcomes following receipt of autologous stem cell transplantation for patients with diffuse large/high grade B cell lymphomaLandsburg, D. J. / Nasta, S. D. / Svoboda, J. / Schuster, S. J. / Gerson, J. N. / Chong, E. A. / Barta, S. K. / Cunningham, K. / Garfall, A. L. / Stadtmauer, E. A. et al. | 2023
- 447
-
Autologous hematopoietic cell transplantation (autoHCT) for T‐cell/histiocyte‐rich large B‐cell lymphoma (THRLBCL): An EBMT Lymphoma Working Party studyRenders, S. / Finel, H. / Ngoya, M. / Boumendil, A. / Schaap, N. / Ghesquieres, H. / Bloor, A. / Pérez‐Simón, J. A. / Huynh, A. / Kobbe, G. et al. | 2023
- 448
-
Outcomes of diffuse large/high grade B cell lymphoma patients following receipt of autologous stem transplantation or chimeric antigen receptor‐modified T cellsLandsburg, D. J. / Nasta, S. D. / Svoboda, J. / Gerson, J. N. / Schuster, S. J / Barta, S. K / Chong, E. A. / Difilippo, H. / Weber, E. / Cunningham, K. et al. | 2023
- 449
-
Prognostic factors for cellular therapies ‐ CART and allogeneic SCT ‐ in relapsed /refractory large B cell lymphoma (LBCL)Glass, B. / Sureda, A. / Boumendil, A. / Dreger, P. / Corradini, P. / Ram, R. / Kroeger, N. / Castagna, L. / Pabst, T. / Kwon, M. et al. | 2023
- 451
-
Comparison of overall survival of lisocabtagene maraleucel (liso‐cel) versus standard of care (SOC) adjusting for crossover in second‐line (2L) R/R large B‐cell lymphomaMorschhauser, F. / Ghesquieres, H. / Kamdar, M. / Liu, F. F. / Chandler, C. / Crotta, A. / Klijn, S. L. / Elsada, A. / Previtali, A. / Chaillol, I. et al. | 2023
- 452
-
CAR T treatment access and outcomes in patients with large B‐cell lymphoma according to ethnicity and socioeconomic deprivationDragoi, D. / Cusworth, S. / Amrith, M. / Sanderson, R. / Paneesha, S. / Patten, P. / Potter, V. / Hardefeldt, P. / Yallop, D. / Chaganti, S. et al. | 2023
- 453
-
Efficacy of Subcutaneous Epcoritamab versus Axi‐cel in R/R DLBCL CAR T‐Naive and CAR T‐eligible patients: An Indirect ComparisonThieblemont, C. / Fox, C. P. / Wang, A. / Sail, K. / Alshreef, A. / Moran, M. / Mutebi, A. / Blaedel, J. / Chirikov, V. / Salles, G. et al. | 2023
- 453
-
Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myelomaKauer, Joseph / Sester, Lilli Sophie / Kriegsmann, Katharina / Weinhold, Niels / Ober, Michael / Müller‐Tidow, Carsten / Goldschmidt, Hartmut / Raab, Marc‐Steffen / Sauer, Sandra et al. | 2023
- 454
-
Efficacy and toxicity of CAR T‐cell therapy in patients with primary and secondary central nervous system lymphoma—an analysis of the EBMT Lymphoma WP and the GoCART coalitionLaube, A. / Fuhrmann, S. / Peczynski, C. / Boumendil, A. / Michel, E. / Finel, H. / Galimard, J. / Beauvais, D. / Daskalakis, M. / Novak, U. et al. | 2023
- 456
-
Treatment with anti CD19 CAR‐T cells is safe and effective in patients with relapsed refractory large B‐cell lymphoma with active central nervous system involvementMarieton, E. Robin / Le Bras, F. / Malfuson, J. / Camus, V. / Legendre, H. / Degoutte, C. / Gounot, R. / Belhadj, K. / Sibon, D. / Dupuis, J. et al. | 2023
- 457
-
Efficacy and safety of Axicabtagene ciloleucel (Axi‐cel) for the treatment of relapse/refractory non‐Hodgkin lymphoma: First real‐world data in Chinese populationZhao, W. L. / Li, Y. H. / Zou, D. H. / Zhu, X. J. / Ji, D. M. / Qian, W. B. / Lu, Y. / Ji, C. Y. / Zhou, K. S. / Jing, H. M. et al. | 2023
- 458
-
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment for chronic lymphocytic leukemia/ small lymphocytic leukemia: a single‐arm studyYi, M. / Xia, Y. / Sha, Y. / Qin, S. / Jiang, R. / Qiu, T. / Wu, W. / Qiu, J. / Yang, Y. / Ding, C. et al. | 2023
- 459
-
Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B‐cell malignancies: Post hoc analysis of a large clinical trial safety databaseBrown, J. R. / Eichorst, B. / Ghia, P. / Jurczak, W. / Kahl, B. S. / Lamanna, N. / Robak, T. / Shadman, M. / Tam, C. S. / Qiu, L. et al. | 2023
- 461
-
Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trialsTedeschi, A. / Ahn, I. E. / Fraser, G. A. M. / Greil, R. / Munir, T. / Kay, N. E. / Flinn, I. W. / Lee, S. / Saifan, C. / Kearbey, J. et al. | 2023
- 463
-
Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromesLee, Wan‐Hsuan / Lin, Chien‐Chin / Wang, Yu‐Hung / Yao, Chi‐Yuan / Kuo, Yuan‐Yeh / Tseng, Mei‐Hsuan / Peng, Yen‐Ling / Hsu, Cheng‐An / Sun, Hsun‐I / Chuang, Yi‐Kuang et al. | 2023
- 463
-
Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): Impact on health‐related quality of lifeEichhorst, B. / Lamanna, N. / O'Brien, S. M. / Tam, C. S. / Qiu, L. / Yang, K. / Wu, K. / Salmi, T. / Barnes, G. / Brown, J. R. et al. | 2023
- 464
-
Ibrutinib (Ibr) for treatment of relapsed‐refractory (R/R) chronic lymphocytic leukemia (CLL): a matching‐adjusted indirect comparison of 3 randomized phase 3 trialsGhia, P. / Munir, T. / Burger, J. / Seymour, J. F. / Rogers, K. / Huang, H. / Moreno, C. / Neumayr, L. / Abbazio, C. / Sharman, J. et al. | 2023
- 466
-
Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter SyndromeDavids, M. S. / Rogers, K. A. / Jain, N. / Tyekucheva, S. / Ren, Y. / Carey, C. / Montegaard, J. / Hajdenberg, M. / Ryan, C. E. / Merryman, R. et al. | 2023
- 468
-
Safety of acalabrutinib treatment in very old (≥80 y) and/or frail patients with chronic lymphocytic leukemia ‐ interim safety analysis of the ongoing phase II CLL‐Frail trialSimon, F. / Ligtvoet, R. / Nösslinger, T. / Bohn, J. / von Tresckow, J. / Liersch, R. / Gaska, T. / Jentsch‐Ullrich, K. / Koenigsmann, M. / Wolff, T. et al. | 2023
- 469
-
A phase 2 study of zanubrutinib in previously treated B‐cell malignancies intolerant to ibrutinib and/or acalabrutinib: Preliminary results for patients with CLL/SLLShadman, M. / Burke, J. M. / Zafar, S. F. / Misleh, J. / Rao, S. S. / Farber, C. M. / Cohen, A. / Crescenzo, R. / By, K. / Flinn, I. W. et al. | 2023
- 471
-
Timing of disease progression and impact on survival in Swedish mantle cell lymphoma patients—a novel illness‐death model studyEkberg, S. / Glimelius, I. / Albertsson‐Lindblad, A. / Weibull, C. E. et al. | 2023
- 472
-
Multicohort Study of Conditional Survival and Cause of Death After Achieving Event‐Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL)Wang, Y. / Larson, M. C. / Ekberg, S. / Smedby, K. E. / Zhao, E. J. / Gerrie, A. S. / Farooq, U. / Maurer, M. J. / Paludo, J. / Nowakowski, G. S. et al. | 2023
- 474
-
Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD studyVisco, C. / Malinverni, C. / Florea, E. / Glimelius, I. / Mirandola, M. / Ekström‐Smedby, K. / Tisi, M. C. / Giné, E. / Albertsson‐Lindblad, A. / Niebla, A. Marin et al. | 2023
- 474
-
Heat shock protein 90 inhibitors induce cell differentiation via the ubiquitin‐dependent aurora kinase A degradation in a MPLW515L mouse model of primary myelofibrosisWang, Fuping / Zhang, Haotian / He, Binghong / Liu, Zihan / Wu, Xinxin / Liu, Yuankai / Xu, Xin / Gou, Xiaoxue / Wang, Haitao / Yang, Qiong et al. | 2023
- 475
-
Secondary malignancies in mantle cell lymphoma patients—A nationwide population‐based study in SwedenAbalo, K. / Smedby, K. E. / Ekberg, S. / Eloranta, S. / Pahnke, S. / Albertsson‐Lindblad, A. / Jerkeman, M. / Glimelius, I. et al. | 2023
- 476
-
How to choose between curative radiotherapy or chemotherapy in low stage MCL?—a population‐based analysis of outcome in patients with stage I‐II MCL in SwedenAlbertsson‐Lindblad, A. / Ekberg, S. / Glimelius, I. / Ellin, F. / Sonnevi, K. / Lewerin, C. / Smedby, K. E. / Jerkeman, M. et al. | 2023
- 477
-
Enhanced ctDNA Profiling Reveals Molecular Determinants of Response and Resistance in Relapsed and Refractory Mantle Cell Lymphoma (NLG‐MCL7‐VALERIA)Meriranta, L. / Kolstad, A. / Hutchings, M. / Pasanen, A. / Niemann, C. Utoft / Riise, J. / Christensen, J. Haaber / Wader, K. Fahl / Glimelius, I. / Leppä, S. et al. | 2023
- 478
-
Long term follow‐up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combinationLe Gouill, S. / Morschhauser, F. / Chiron, D. / Bouabdallah, K. / Cartron, G. / Casasnovas, O. / Rule, S. / Bodet‐Milin, C. / Herbaux, C. / Gastinne, T. et al. | 2023
- 480
-
Long‐term safety with ≥12 months of pirtobrutinib in relapsed/refractory B‐cell malignanciesWang, Y. / Coombs, C. C. / Shah, N. N. / Jurczak, W. / Woyach, J. / Cheah, C. Y. / Patel, K. / Maddocks, K. / Muehlenbein, C. E. / Wang, C. et al. | 2023
- 481
-
Long‐term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.Carras, S. / Torroja, A. / Emadali, A. / Daguindau, N. / Tempescul, A. / Macro, M. / Moreau, A. / Tchernonog, E. / Houot, R. / Schmitt, A. et al. | 2023
- 483
-
Rituximab combined with chemotherapy and acalabrutinib prior to autologous stem cell transplantation in mantle cell lymphoma: The Rectangle TrialVilla, D. / Larouche, J. F. / Cheung, M. / Keating, M. M. / Zukotynski, K. / Tonseth, P. / Mayo, S. / Laister, R. / Scott, D. / Kuruvilla, J. et al. | 2023
- 484
-
Venetoclax based combination therapy does not overcome poor outcomes in BTKi‐refractory mantle cell lymphoma: phase 2 trial of umbralisib, ublituximab, and venetoclaxWallace, D. S. / Rowland, C. / Hill, B. T. / Baran, A. M. / Casulo, C. / Reagan, P. M. / Winter, A. / Karmali, R. / Winter, J. N. / Gordon, L. I. et al. | 2023
- 486
-
Analysis of immune and high‐risk biomarkers in patients with relapsed or refractory mantle cell lymphoma treated with glofitamab monotherapyPham*, T. H. / Leung*, W. / Hamidi, H. / Dickinson, M. / Morschhauser, F. / Carlo‐Stella, C. / Humphrey, K. / Mulvihill, E. / Lundberg, L. / Filezac de L’Etang, A. et al. | 2023
- 487
-
Using natural killer cell‐derived exosomes as a cell‐free therapy for leukemiaSamara, Aladin / Anbar, Michael / Shapira, Saar / Zemlyansky, Anna / Zozovsky, Alla / Raanani, Pia / Granot, Galit / Rozovski, Uri et al. | 2023
- 488
-
Real‐world outcomes of brexucabtagene autoleucel (brexu‐cel) for relapsed or refractory mantle cell lymphoma (r/r MCL): A CIBMTR subgroup analysis by prior treatmentAhmed, N. / Kambhampati, S. / Hamadani, M. / Grover, N. / Shadman, M. / Locke, F. L. / Gerson, J. / Frank, M. J. / Budde, L. E. / Wang, M. et al. | 2023
- 490
-
Outcomes of Bridging and Salvage Radiotherapy in Relapsed or Refractory Mantle Cell Lymphoma Patients Undergoing CD19‐Targeted CAR T‐Cell TherapyAbabneh, H. S. / Frigault, M. / Patel, C. G. et al. | 2023
- 491
-
Long term outcome of Peripheral T Cell Lymphomas: 10y follow‐up analysis of the International Prospective T Cell Project NetworkCivallero, M. / Advani, R. / Horwitz, S. / Manni, M. / Cabrera, M. E. / Vose, J. / Spina, M. / Hits, F. / Nagler, A. / Montoto, S. et al. | 2023
- 492
-
Diagnosis and management of adult T‐cell leukemia/lymphoma in a Brazilian Cohort. T‐cell Brazil ProjectChiattone, C. S. / Miranda, E. C. M. / Gonzaga, Y. B. M. / Baptista, R. L. R. / Dias, M. / Nogueira, F. L. / Borducchi, D. / Bellesso, M. / Duffles, G. / Pereira, J. et al. | 2023
- 493
-
Newly diagnosed extranodal natural killer/T cell lymphoma (ENKTL) treated by anti‐PD‐1 antibody plus histone deacetylase inhibitor followed by P‐GemOx regimenGao, Y. / Zhang, Y. / Wang, X. / Bai, B. / Zhang, X. / Huang, Y. / He, Y. / Ping, L. / Huang, C. / Chen, H. et al. | 2023
- 494
-
Enteropathy associated T‐cell lymphoma: a population‐based cohort study on incidence, treatment and outcome in The NetherlandsMeeuwes, F. O. / Brink, M. / Plattel, W. J. / Vermaat, J. S. P. / Kersten, M. J. / Wondergem, M. / Visser, O. / van der Poel, M. W. M. / Oostvogels, R. / Woei‐A‐Jin, F. J. S. H. et al. | 2023
- 495
-
Comparison of CHOP‐like with or without Tucidinostat in the first‐line treatment of Peripheral T‐cell lymphoma: a retrospective propensity score‐matched studyWen, X. / Yu, Q. / Wang, J. / Zheng, M. / Zhao, J. / Ma, L. / Su, L. et al. | 2023
- 496
-
Role of upfront autologous stem cell transplantation (ASCT) in adults with T‐NHL in first complete remission (CR1): A systematic literature review and meta‐analysisMichelle, P. L. / Koh, L. P. / Girard, L. / koh, Y. J. / Samuel, M. et al. | 2023
- 497
-
A randomized phase II trial of CHOP versus ICED and autologous stem cell transplantation in newly diagnosed T‐cell lymphomaYoo, K. H. / Kim, S. J. / Jo, J. / Yoon, D. H. / Yang, D. / Yoon, S. E. / Lee, G. / Park, Y. / Kang, K. / Lee, H. et al. | 2023
- 499
-
Chemoresistance in acute myeloid leukemia: An alternative single‐cell RNA sequencing approachCheng, Po‐Liang / Hsiao, Tzu‐Hung / Chen, Chung‐Hsing / Hung, Miao‐Neng / Jhan, Pei‐Pei / Lee, Li‐Wen / Wu, Ting‐Shuan / Tsai, Jia‐Rung / Teng, Chieh‐Lin Jerry et al. | 2023
- 499
-
Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histologyMehta‐Shah, N. / Jacobsen, E. D. / Zinzani, P. L. / Zain, J. / Mead, M. / Casulo, C. / Gritti, G. / Pinter‐Brown, L. / Izutsu, K. / Waters, S. et al. | 2023
- 500
-
Improved prognosis of advanced‐stage extranodal NK/T‐cell lymphoma: results of the NKEA‐Next studyFujimoto, A. / Miyazaki, K. / Taguchi, S. / Asano, N. / Yakushijin, K. / Fujino, T. / Munakata, W. / Ejima, Y. / Hirano, M. / Kubota, N. et al. | 2023
- 502
-
Efficacy of anti‐PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSAMarouf, A. / Chaubard, S. / Michot, J. / Liévin, R. / Rossignol, J. / Golfier, C. / Allangba, O. / Philippe, L. / Tessoulin, B. / Chauchet, A. et al. | 2023
- 503
-
Pegarspargase and sintilimab for newly diagnosed, advanced stage natural killer T‐cell lymphoma, nasal type: an open‐label, single‐arm, phase 2 studyXiong, J. / Cheng, S. / Wang, L. / Xu, P. / Zhao, W. et al. | 2023
- 503
-
Interim analysis of a prospective multicenter phase II study for advanced‐stage or relapsed/refractory natural killer/T cell lymphomaLiu, W. / Zhao, L. / Wu, C. / Yu, H. / Li, Z. / Liu, L. / Gao, D. / Sun, Y. / Wei, X. / Wu, Y. et al. | 2023
- 504
-
Imatinib‐induced complete and long‐term sustained remission in chemotherapy‐resistant systemic ALK‐positive anaplastic large cell lymphomaPichler, A. / Kornauth, C. / Garces‐de‐los‐Fayos‐Alonso, I. / Kazianka, L. / Alachram, H. / Zibat, A. / Pemovska, T. / Heller, G. / Greil, R. / Kenner, L. et al. | 2023
- 505
-
Brigatinib in patients with ALK‐positive anaplastic large cell lymphoma who have failed brentuximab vedotinVeleanu, L. / Tesson, B. / Lamant, L. / Marçais, A. / Bruneau, J. / Kaltenbach, S. / Brouzes, C. / Degoutte, C. / Moraly, J. / Villarese, P. et al. | 2023
- 506
-
Long‐term outcomes with mogamulizumab alone or in combination with other therapies for the treatment of cutaneous t‐cell lymphomaBojanini, L. / Herrera, M. / Li, S. / Xu, N. / Ahmed, A. A. / Khodadoust, M. / Kim, Y. H. et al. | 2023
- 508
-
Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of advanced extranodal NK/T‐cell lymphomaFu, R. / Liang, Y. / Wei, L. / Piao, Y. / Wang, L. et al. | 2023
- 509
-
Safety and efficacy of brentuximab vedotin in Chinese adults with CD30+ peripheral T‐cell lymphoma: an interim analysis from a prospective, observational, real‐world studyCai, M. / Cui, G. / Liu, L. / Li, Z. / Bai, O. / Lu, Y. / Shi, K. / Wang, J. / Zhang, W. / Zhao, W. et al. | 2023
- 510
-
Knockdown of let‐7b in leukemia associated macrophages inhibit acute myeloid leukemia progressionTian, Chen / Li, Yueyang / Si, Junqi / Kang, Junnan / Chen, Zehui / Nuermaimaiti, Rexidan / Wang, Yafei / Yu, Yong / Zhao, Zhigang / Wang, Xiaofang et al. | 2023
- 511
-
Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCLTolu, S. S. / Seshadri, M. R. / Chen, Z. / Orlando, E. / Grenet, J. / Toor, R. / Sanjurjo, A. / Phillips, A. / Shore, T. / Martin, P. et al. | 2023
- 512
-
Allogeneic transplantation in T‐cell lymphoma: Lessons from the AATT studyTournilhac, O. / Altmann, B. / Friedrichs, B. / Bouabdallah, K. / Cartron, G. / Nickelsen, M. / Wulf, G. / Leclerc, M. / Vilatte, A. / Turlure, P. et al. | 2023
- 513
-
Predictors of response to radiation therapy and of progression to multiple myeloma in patients with solitary bone and extramedullary plasmacytomasFregonese, B. / Imber, B. / Lee, J. / Zhang, Z. / Toumbacaris, N. / Yahalom, J. / Hajj, C. et al. | 2023
- 515
-
SAR444245, a non‐alpha IL2, rescues chronic antigen and CAR‐driven T‐cell dysfunctionSheikh, I. / Choi, A. / Reville, P. K. / Henderson, J. / Rojas, E. / Le, C. / Okwuchi, C. / Carrio, R. / Pate, N. / Malley, K. et al. | 2023
- 515
-
Radiation in a new era of Multiple Myeloma management: Patterns of utilization, clinical, radiologic, and biochemical outcomes, and possible genomic correlates of responseDreyfuss, A. D. / Fregonese, B. / Ma, J. / Reith, S. / Cederquist, G. / Hubbeling, H. / Tringale, K. R. / Wijetunga, N A. / Usmani, S. / Hajj, C. et al. | 2023
- 517
-
Cellular dynamics and their impact on outcome in patients with mantle cell lymphoma during treatment with chimeric antigen receptor (CAR) T cellsWeiss, R. / Fernandez, C. P. / Boldt, A. / Hoffmann, S. / Krauss, S. / Bach, E. / Kirchberg, J. / Kurch, L. / Merz, M. / Metzeler, K. et al. | 2023
- 518
-
Responses after Allogeneic NK Cell Therapy for Lymphoma: correlative analysis revealed impact of host monocytes and robust T cells tumor traffickingBachanova, V. / Cao, Q. / Miller, J. / Maakaron, J. / Felices, M. / Wangen, R. / Larson, M. / Simantov, R. / Mazor, R. D. / Tilahun, A. et al. | 2023
- 519
-
The Italian CART‐SIE real life multicenter observational study on Chimeric Antigen Receptor T‐cell (CAR‐T) therapy for large B‐cell (LBCL) and mantle cell (MCL) lymphomasChiappella, A. / Dodero, A. / Ljevar, S. / Pennisi, M. / Bonifazi, F. / De Philippis, C. / Galli, E. / Di Rocco, A. / Tisi, M. C. / Cutini, I. et al. | 2023
- 520
-
Capitalizing on paradoxical activation of the mitogen‐activated protein kinase pathway for treatment of Imatinib‐resistant mast cell leukemiaWilhelm, Thomas / Toledo, Marcelo A. S. / Simons, Ilka / Stuth, Christian / Mohta, Vrinda / Mülfarth, Ronja / Nitsche, Marcus / Maschke‐Neuß, Karin / Schmitz, Susanne / Kaiser, Anne et al. | 2023
- 520
-
3‐Year outcomes of adults with relapsed or refractory B‐cell acute lymphoblastic leukemia treated with brexu‐cel in ZUMA‐3 by age, prior therapies, and subsequent transplantShah, B. D. / Cassaday, R. D. / Park, J. H. / Houot, R. / Oluwole, O. O. / Logan, A. C. / Boissel, N. / Leguay, T. / Bishop, M. R. / Topp, M. S. et al. | 2023
- 522
-
Matching‐adjusted indirect comparison of axicabtagene ciloleucel versus mosunetuzumab in relapsed/refractory follicular lymphoma patients after 2 prior systemic treatmentsRay, M. D. / Kanters, S. / Beygi, S. / Best, T. / Wulff, J. / Limbrick‐Oldfield, E. H. / Patel, A. R. / Oluwole, O. O. et al. | 2023
- 523
-
Outcomes in patients with EBV+ PTLD treated with allogeneic EBV‐specific T‐cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in EuropeChoquet, S. / Clark, A. / Renard, C. / Uttenthal, B. / Chaganti, S. / Trappe, R. U. / Comoli, P. / Duan, X. / Xing, B. / Wu, C. et al. | 2023
- 524
-
Combined autologous CD30.CAR‐T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study)Ahmed, S. / Mei, M. / Kurtz, D. M. / Beitinjaneh, A. / Grover, N. S. / Ramos, C. A. / Chabon, J. J. / Schultz, A. / Ding, C. / Myo, A. et al. | 2023
- 526
-
First in human data of NKX019, an allogeneic CAR NK for the treatment of relapsed/refractory (R/R) B‐cell malignanciesDickinson, M. / Hamad, N. / Bryant, C. E. / Kothari, N. / Ojeras, P. / Vohra, A. / Lin, M. / Tohme, M. / Trager, J. / Shook, D. et al. | 2023
- 527
-
A Phase I Study of CD19‐targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B‐cell LymphomaPalomba, M. L. / Riviere, I. / Sikder, D. S. / Senechal, B. / Wang, X. / Cathcart, E. R. / Liotta, K. / Li, J. / Sellner, L. / Sadelain, M. et al. | 2023
- 528
-
Outcomes with bendamustine lymphodepletion and brexucabtagene autoleucel for mantle cell lymphomaChong, E. A. / Gerson, J. N. / Nasta, S. D. / Landsburg, D. J. / Barta, S. K. / Svoboda, J. / Weber, E. / Ghilardi, G. / Ruella, M. / Porter, D. L. et al. | 2023
- 529
-
Reasons for Discordance Among Imaging‐based Response Criteria In Lymphoma Patients Receiving CAR T‐cell TherapyWinkelmann, M. / Blumenberg, V. / Rejeski, K. / Buecklein, V. / Schmidt, C. / Dekorsy, F. / Bartenstein, P. / Ricke, J. / von Bergwelt‐Baildon, M. / Subklewe, M. et al. | 2023
- 530
-
CNS radiotherapy as bridging prior to CAR T‐cell therapy for hematologic malignanciesCederquist, G. / Hubbeling, H. / Tringale, K. / Shah, G. / Tomas, A. Alarcon / Shouval, R. / Hajj, C. / Fregonese, B. / Lee, J. / Dahi, P. B. et al. | 2023
- 532
-
Multicenter experience with radiotherapy for relapse after chimeric antigen receptor T cell therapy in non‐Hodgkin lymphomaHubbeling, H. / Figura, N. / Ladbury, C. / Keit, E. R. / Chew, J. / Fregonese, B. / Silverman, E. A. / Hajj, C. / Shah, G. / Kambhampati, S. et al. | 2023
- 532
-
Developing CAR‐T‐sparing Radiotherapy ‐ early dosimetric resultsMikhaeel, N. G. / Ntentas, G. / Sivabalasingham, S. / Brady, J. L. / Tait, J. / De Farias, M. Correia / Roddie, C. / Sanderson, R. / Kuhnl, A. et al. | 2023
- 534
-
Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.Vic, S. / Thibert, J. / Bachy, E. / Cartron, G. / Gastinne, T. / Morschhauser, F. / Le Bras, F. / Bouabdallah, K. / Despas, F. / Bay, J. et al. | 2023
- 534
-
Predicting ICANS by means of plasma CAR‐T cell derived extracellular vesicles in patients undergoing infusion of anti‐CD19 CAR‐T cellsDe Felice, F. / Storci, G. / Ricci, F. / Tazzari, P. L. / De Matteis, S. / Bertuccio, S. N. / Rossini, L. / Tomassini, E. / Dicataldo, M. / Laprovitera, N. et al. | 2023
- 535
-
Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working groupYanagisawa, Ryu / Tamaki, Masaharu / Tanoshima, Reo / Misaki, Yukiko / Uchida, Naoyuki / Koi, Satoshi / Tanaka, Takashi / Ozawa, Yukiyasu / Matsuo, Yayoi / Tanaka, Masatsugu et al. | 2023
- 536
-
Neurotoxicity in patients with CNS lymphomas treated with CAR‐T cell therapy. A LOC network studyTost, H. Hernandez / Weiss, N. / Choquet, S. / Ribeiro, M. / Birzu, C. / Le Guennec, L. / Shor, N. / Morel, V. / Solorzano, S. / Souchet, L. et al. | 2023
- 537
-
Factors Associated with Increased Risk of Major Cardiovascular Events for Patients Undergoing CAR T TherapyReves, H. / Eljalby, M. / Rao, A. / Chandra, A. / Zhang, K. / Muquith, M. / Jackson, M. / Geethakumari, P. Ramakrishnan / Afrough, A. / Anderson, L. D. Jr. et al. | 2023
- 538
-
Health‐related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso‐cel in TRANSCEND CLL 004Maloney, D. G. / Siddiqi, T. / Fakhri, B. / Ma, S. / Shah, N. N. / Riedell, P. A. / Schuster, S. J. / Eliason, L. / Wang, L. / Tuazon, S. A. et al. | 2023
- 541
-
‘Don’t keep me waiting’: estimating the impact on lifetime survival and QALYs of reduced vein‐to‐vein time for LBCL patients treated with CAR T in the 3L+ settingMaziarz, R. / Vadgama, S. / Pasquini, M. / Hu, Z. / Ray, M. / Smith, H. / Bullement, A. / Edmondson‐Jones, M. / Sullivan, W. / Cartron, G. et al. | 2023
- 542
-
Remote monitoring of CAR T‐cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA programColin, F. / Bellec, A. / Le Bars, L. / Granger, M. / De Guibert, S. / Manson, G. / Lhomme, F. / Marchand, T. / Mear, J. / Barbe, M. Escoffre et al. | 2023
- 542
-
Drug‐resistance mutations in BTK occur in distinct enzymatic classes and are overcome by BTK degradationMontoya, S. / Bourcie, J. / Sondhi, A. / Jahn, J. / Alencar, A. / Abdel‐Wahab, O. / Taylor, J. et al. | 2023
- 544
-
BTM 3566, a Novel Activator of the Mitochondrial Stress Response Induces Robust Therapeutic Responses in Diffuse Large B‐cell Lymphoma in vitro and in vivoBashir, Z. / Schwarzer, A. / Oliveria, M. / Kleppa, M. / Anantha, A. / Kostura, M. / Stocum, M. / Hembrough, T. et al. | 2023
- 544
-
MALT1 protease inhibition overcomes BTK inhibitor resistance and shows synergistic activity with venetoclax in models of B cell lymphoma and leukemiaPlotnik, J. / Bontcheva1, V. / Dowell, C. / Chen, J. / Richardson, A. / McClure, R. / Jung, P. / Pham, L. / Souers, A. / Meulbroek, J. et al. | 2023
- 546
-
Diffuse large B‐cell lymphoma cell‐cycle progression requires the cyclin‐G associated kinase (GAK), a novel drug target from machine learning‐enabled phenotypic screeningLightfuss, O. B. / Newsam, A. / Kumar, P. / Li, L. / Ghoshal, A. / Alaoui, A. Y. / Schürer, S. / Lemmon, V. / Maura, F. / Feng, Y. et al. | 2023
- 546
-
BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient‐Derived ModelsMa, J. / Lu, M. / Chen, L. / Geng, H. / Kumar, A. / Noviski, M. / Rountree, R. / Guiducci, C. / Rubenstein, J. et al. | 2023
- 546
-
15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center studyMei, Chen / Ye, Li / Ren, Yanling / Zhou, Xinping / Ma, Liya / Xu, Gaixiang / Xu, Weilai / Lu, Chenxi / Yang, Haiyang / Luo, Yingwan et al. | 2023
- 547
-
Differential ibrutinib sensitivity in Cd79b‐mutant and wildtype subtypes of a novel Myd88‐driven DLBCL mouse modelFlümann, R. / Hansen, J. / Klein, S. / Goldfarb‐Wittkopf, H. / Pfeiffer, P. / Wirtz, J. / Lütz, A. F. / Persigehl, T. / Büttner, R. / Jachimowicz, R. et al. | 2023